{"study_id": 75699, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to examine the efficacy of N-acetylcysteine (NAC) as an adjunctive therapy for treating bipolar depression.", "results_summary": "The study found no significant improvement in symptomatology, functioning, or quality of life from adding NAC to standard therapy for bipolar depression. The results did not support NAC as an effective adjunctive treatment for this condition.", "population_specificity": "Patients with diagnosed bipolar disorder experiencing a current depressive episode.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:24.295898+00:00"}
{"study_id": 75700, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to investigate the effects of N-acetylcysteine (NAC) as an antioxidant in the treatment of acne vulgaris, focusing on its mechanisms and potential benefits.", "results_summary": "The study found that NAC increases glutathione levels, reduces inflammatory cytokines, and exhibits antibacterial activity, showing beneficial effects in treating acne vulgaris and its complications.", "population_specificity": "Patients with acne vulgaris (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:24.684725+00:00"}
{"study_id": 75693, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to systematically review the protective effects of N-Acetylcysteine (NAC) on occupational noise-induced hearing loss (NIHL).", "results_summary": "The study found that NAC has a considerable protective effect on NIHL, though the specific protective effects across different frequencies were not specified. The findings for other antioxidants were inconsistent.", "population_specificity": "Occupationally noise-exposed workers (industrial, military, and other job-related noise exposure).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:26.250799+00:00"}
{"study_id": 75701, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 65, "study_goal": "The researchers aimed to review the literature on RARS management, including the role of N-Acetylcysteine among other medical therapies.", "results_summary": "The study found that surgical management (BSD or ESS) showed a trend toward greater symptom control than medical therapies, including N-Acetylcysteine, but meta-analysis was not possible. N-Acetylcysteine's specific efficacy was not detailed.", "population_specificity": "Patients with RARS, aged 5.8 to 53.5 years.", "effective_dosage": "Not specified", "study_duration": "Follow-up ranged from 1 to 19 months (intervention duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:27.230788+00:00"}
{"study_id": 75703, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) could mitigate oxidative stress and systemic inflammation in tuberculosis (TB) patients, particularly those with HIV.", "results_summary": "The abstract suggests that NAC, as a glutathione precursor, shows potential in limiting oxidative stress in experimental models of TB, but full clinical outcomes are not detailed.", "population_specificity": "Persons living with HIV and tuberculosis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:31.437778+00:00"}
{"study_id": 75702, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether standard intravenous N-acetylcysteine (NAC) dosing (300 mg/kg over 21 hours) is effective in preventing hepatotoxicity in cases of massive acetaminophen (APAP) overdose.", "results_summary": "The study found that standard NAC dosing prevented hepatotoxicity in 91% of cases when administered within 8 hours of massive APAP overdose, with 76% of cases showing no acute liver injury or hepatotoxicity. However, 24% of cases still developed hepatotoxicity.", "population_specificity": "Patients with massive APAP overdose (single, acute overdose resulting in APAP concentration exceeding 300 mcg/mL at 4 hours post-ingestion).", "effective_dosage": "300 mg/kg intravenously over 21 hours.", "study_duration": "21 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:31.652908+00:00"}
{"study_id": 75705, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 75, "study_goal": "The researchers aimed to assess the efficacy and safety of N-acetylcysteine in treating chronic pain across various conditions.", "results_summary": "The pooled analysis of three RCTs found no significant reduction in pain intensities, functional outcomes, or quality of life, though sensitivity analysis suggested potential effects for pain and function. Safety conclusions were unclear due to inconsistent adverse event reporting.", "population_specificity": "Adults \u226518 years with chronic pain conditions (sickle cell disease, complex regional pain syndrome, pelvic pain/endometriosis, rheumatoid arthritis, diabetic neuropathy, chronic neuropathic pain).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:32.639960+00:00"}
{"study_id": 75706, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine was effective in reducing the incidence of postoperative acute kidney injury (AKI) in patients undergoing elective abdominal aortic aneurysm (AAA) repair.", "results_summary": "The study found N-Acetylcysteine to be ineffective in preventing postoperative AKI in AAA repair patients, as it was listed among interventions with no significant protective effects. The conclusion was based on pooled data from multiple trials, though the overall quality of evidence was limited by small sample sizes and high risk of bias.", "population_specificity": "Patients undergoing elective AAA repair (open or endovascular approach).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:33.191484+00:00"}
{"study_id": 75707, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the clinical efficacy of N-acetylcysteine (NAC) in treating ST segment elevation myocardial infarction (STEMI).", "results_summary": "NAC significantly reduced all-cause mortality, major adverse cardiovascular events (MACE), and myocardial enzyme hs-TnT levels in STEMI patients, but showed no significant difference in new congestive heart failure, ejection fraction, or CK-MB levels compared to the control group. No significant difference in adverse reactions was observed between NAC and control groups.", "population_specificity": "Patients with ST segment elevation myocardial infarction (STEMI).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:33.511486+00:00"}
{"study_id": 75709, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to explore the potential of N-Acetylcysteine and other nutraceuticals in suppressing inflammasome activity, particularly NLRP3, to mitigate inflammation-related pathologies.", "results_summary": "The abstract suggests N-Acetylcysteine may have clinical potential for suppressing inflammasome activity, alongside other antioxidants and nutraceuticals, but does not provide specific efficacy data for N-Acetylcysteine alone.", "population_specificity": "Not specified (general discussion of inflammasome-related pathologies).", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:35.234367+00:00"}
{"study_id": 75708, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 70, "study_goal": "The researchers aimed to analyze the clinical features, outcomes, and management of newborns and infants exposed to supratherapeutic doses of paracetamol, with a focus on the role of N-acetylcysteine as an antidote.", "results_summary": "N-Acetylcysteine was identified as the treatment of choice for paracetamol poisoning, effectively reducing hepatotoxic effects when administered according to specific weight-based dosing regimens. Newborns and infants with paracetamol concentrations below nomogram limits had low risk of serious hepatic damage, while those with multiple supratherapeutic doses required cautious management.", "population_specificity": "Newborns and infants exposed to supratherapeutic doses of paracetamol.", "effective_dosage": "Weight-based dosing tables (specific amounts not detailed in abstract).", "study_duration": "Not specified in abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:36.139990+00:00"}
{"study_id": 75690, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to evaluate whether early use of N-Acetylcysteine could prevent progression to acute liver failure in non-acetaminophen drug-induced liver injury (DILI).", "results_summary": "The study suggests that early use of N-Acetylcysteine may be useful in preventing progression to acute liver failure in non-acetaminophen DILI, though further research is needed for confirmation.", "population_specificity": "Geriatric population with drug-induced liver injury (DILI), particularly related to herbal and dietary supplement (HDS) use.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:36.415702+00:00"}
{"study_id": 75711, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to review the clinical use and drug-drug interactions of N-Acetylcysteine among other natural supplements in dermatology.", "results_summary": "The study identified that N-Acetylcysteine may interfere with concentrations of other medications used in psychiatric settings, but no specific efficacy outcomes were reported.", "population_specificity": "Not specified (general dermatology context)", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "May interfere with psychiatric medications", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:40.264969+00:00"}
{"study_id": 75710, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of a risk-stratified approach, including N-Acetylcysteine (NAC) infusion, in managing cytokine release syndrome (CRS) in children undergoing haploidentical hematopoietic stem cell transplantation.", "results_summary": "The study found that NAC, combined with low-dose adrenaline and high-flow nasal cannula, contributed to adequate control of CRS, with low mortality (2.2%) and no reported adverse effects specifically linked to NAC.", "population_specificity": "Children up to 18 years of age undergoing haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:40.793255+00:00"}
{"study_id": 75712, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of N-Acetylcysteine (NAC) as a treatment augmentation strategy for bipolar depression through a meta-analysis of clinical trials.", "results_summary": "The meta-analysis of six trials involving 248 patients found that NAC had a moderate effect size (d = 0.45) over placebo in improving depressive symptoms, though with substantial heterogeneity and a large confidence interval. Larger trials are needed to explore moderating factors like dosage and treatment duration.", "population_specificity": "Patients with bipolar depression.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:41.193630+00:00"}
{"study_id": 75713, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the adverse effects profile of N-Acetylcysteine (NAC) at doses higher than the standard 600 mg/day in chronic respiratory diseases to establish a risk-benefit ratio for increased dosing.", "results_summary": "The safety profile of NAC at higher doses (up to 3000 mg/day) was similar to the standard dose, with gastrointestinal symptoms reported but not more frequently than in control groups. The review included 41 studies, primarily on oral NAC, showing comparable safety across doses.", "population_specificity": "Patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, bronchiectasis, chronic bronchitis, and cystic fibrosis.", "effective_dosage": "600 mg/day to 3000 mg/day", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:42.716917+00:00"}
{"study_id": 75715, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of N-Acetylcysteine as a therapeutic agent for bipolar disorder by modulating inflammatory responses.", "results_summary": "The study suggests that N-Acetylcysteine, along with other anti-inflammatory agents, shows promise in treating bipolar disorder by targeting neuroinflammation and immune system dysregulation. However, specific efficacy data for N-Acetylcysteine alone are not detailed.", "population_specificity": "Patients with bipolar disorder", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:42.991901+00:00"}
{"study_id": 75714, "supplement_id": 1364, "safety_score": "65", "efficacy_score": 40, "quality_score": 70, "study_goal": "The researchers aimed to assess the benefits and harms of N-acetylcysteine compared with placebo or no intervention in treating non-paracetamol-induced acute liver failure.", "results_summary": "The study found inconclusive evidence regarding N-acetylcysteine's effect on mortality, liver transplantation rates, or adverse events in both adults and children with non-paracetamol-induced acute liver failure. The certainty of evidence was low due to risk of bias, imprecision, and clinical heterogeneity.", "population_specificity": "Adults and children (birth through age 17 years) with non-paracetamol-induced acute liver failure.", "effective_dosage": "Not specified", "study_duration": "21 days for adults, 1 year for children", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:43.858539+00:00"}
{"study_id": 75718, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to determine the effectiveness of N-Acetylcysteine in preventing noise-induced hearing loss (NIHL) as part of a broader review of pharmacologic agents.", "results_summary": "The study included N-Acetylcysteine among various agents tested for NIHL prevention, but specific efficacy results for N-Acetylcysteine were not highlighted; overall, some pharmacologic interventions showed statistically significant amelioration of NIHL.", "population_specificity": "Patients exposed to various noise conditions (701 total participants across all interventions).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:44.517326+00:00"}
{"study_id": 75716, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 65, "quality_score": 90, "study_goal": "The researchers aimed to determine whether perioperative N-Acetylcysteine infusion improves outcomes, specifically acute kidney injury and early allograft dysfunction, in recipients undergoing live donor liver transplantation.", "results_summary": "NAC infusion significantly reduced postoperative AST and ALT levels and accelerated transaminase normalization, but it did not improve the composite endpoint of acute kidney injury or early allograft dysfunction compared to placebo.", "population_specificity": "Recipients undergoing live donor liver transplantation (150 patients).", "effective_dosage": "Initial loading dose of 150 mg/kg/h over 1 h, followed by 12.5 mg/kg/h for 4 h, then 6.25 mg/kg/h for 91 h.", "study_duration": "96 hours (4 days).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:45.481727+00:00"}
{"study_id": 75722, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the therapeutic potential of N-Acetylcysteine (NAC) in treating COVID-19 by examining its multisite pharmacological actions.", "results_summary": "The study suggests NAC has potential in inhibiting COVID-19 progression due to its pharmacological activities, but no specific clinical efficacy data or outcomes are provided.", "population_specificity": "Not specified (general COVID-19 context).", "effective_dosage": "Not provided.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:48.466082+00:00"}
{"study_id": 75719, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine (NAC) as part of an inhalable multi-drug formulation for treating bacterial biofilms in pulmonary infections, focusing on its mucolytic and anti-inflammatory properties.", "results_summary": "NAC, when combined with curcumin and antibiotics, showed potential to inhibit TNF-\u03b1, IL-8, and IL-1\u03b2 release, but did not enhance the antibacterial activity of azithromycin or ciprofloxacin. The formulation was biocompatible at concentrations up to 32 \u00b5g/mL.", "population_specificity": "P. aeruginosa bacterial biofilms (in vitro study on macrophage-like cells).", "effective_dosage": "Up to 32 \u00b5g/mL (concentration tested for biocompatibility).", "study_duration": "20 hours (exposure time for biocompatibility testing).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:50.312020+00:00"}
{"study_id": 75721, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the pharmacokinetics and tolerability of N-Acetylcysteine (NAC) between healthy Chinese and Caucasian individuals after single and repeated oral doses.", "results_summary": "Pharmacokinetic characteristics of NAC were similar in both Chinese and Caucasian participants, with rapid absorption and higher exposure after multiple doses. NAC showed a favorable tolerability profile, with only minor adverse events reported in two Caucasian participants and none in Chinese participants.", "population_specificity": "Healthy adult volunteers (15 Chinese and 15 Caucasian, mostly Italian; 66.7% male, mean age 36.8 years).", "effective_dosage": "600-mg uncoated tablets, administered as a single dose followed by twice daily for 3 days after a 48-hour wash-out period.", "study_duration": "Single dose plus 3 days of twice-daily administration.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:51.705043+00:00"}
{"study_id": 75725, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to assess the effect of N-acetylcysteine (NAC) on remission maintenance in ulcerative colitis (UC) patients during steroid tapering.", "results_summary": "NAC significantly reduced relapse rates, endoscopic relapse, and inflammatory markers (fecal calprotectin, hs-CRP) compared to placebo, demonstrating efficacy in maintaining remission.", "population_specificity": "UC patients on high-dose corticosteroids and Mesalamine during flare-up management.", "effective_dosage": "800 mg NAC daily.", "study_duration": "16 weeks of intervention, with 6 weeks of post-intervention follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:52.166619+00:00"}
{"study_id": 75723, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the mechanism of acetaminophen-induced liver toxicity and the role of N-Acetylcysteine (NAC) as an antidote for overdose.", "results_summary": "The study found that N-Acetylcysteine effectively counteracts acetaminophen-induced liver toxicity by replenishing glutathione and preventing covalent binding of reactive metabolites to proteins. NAC was introduced as a successful antidote for APAP overdose.", "population_specificity": "Not specified (general mechanism study, likely preclinical or clinical overdose cases).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:52.494958+00:00"}
{"study_id": 75724, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the preventive effect of N-acetylcysteine (NAC) on contrast-associated acute kidney injury (CA-AKI) and mortality in patients with STEMI undergoing primary percutaneous coronary intervention (PPCI).", "results_summary": "NAC significantly reduced the incidence of CA-AKI by 49% and all-cause in-hospital mortality by 63%, though its effect on dialysis requirement was not statistically significant. Subgroup analyses indicated greater benefits in patients with renal dysfunction and those receiving higher oral doses of NAC.", "population_specificity": "Patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).", "effective_dosage": "Higher dosage (specific amount not mentioned) and oral administration were noted as more effective.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:52.636905+00:00"}
{"study_id": 75726, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 70, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) is effective in preventing antitubercular therapy-related drug-induced liver injury (ATT-DILI).", "results_summary": "The study found that NAC significantly reduced the odds of hepatotoxicity compared to controls/placebo, suggesting it is beneficial in preventing ATT-DILI. However, the results were limited by potential bias, variable definitions of ATT-DILI, and a limited number of studies.", "population_specificity": "Patients undergoing antitubercular therapy (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:53.593596+00:00"}
{"study_id": 75727, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of N-acetylcysteine as an antioxidant and anti-inflammatory agent to reduce neonatal morbidity and mortality in patients with clinical chorioamnionitis.", "results_summary": "The study suggests that antenatal administration of N-acetylcysteine may reduce neonatal morbidity and mortality, but well-powered randomized controlled trials are needed to confirm these effects.", "population_specificity": "Pregnant individuals with clinical chorioamnionitis between 24 0/7 and 33 6/7 weeks of gestation, and possibly between 23 0/7 and 23 6/7 weeks.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:54.451322+00:00"}
{"study_id": 75728, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the role of N-Acetylcysteine as part of treatment strategies for disorders of sulfur-containing amino acid metabolism.", "results_summary": "The study suggests N-Acetylcysteine may be beneficial in treating certain metabolic disorders by addressing deficiencies in cysteine or glutathione, but it does not provide specific efficacy data.", "population_specificity": "Patients with disorders of sulfur-containing amino acid metabolism (e.g., defects in methionine demethylation, homocysteine remethylation, or cysteine catabolism).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:57.478095+00:00"}
{"study_id": 75729, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the protective and therapeutic efficacy of N-Acetylcysteine (NAC) against the toxicity of sulphur mustard (H), particularly its long-term lung effects in exposed individuals.", "results_summary": "NAC demonstrated consistent protective properties against sulphur mustard toxicity, particularly in mitigating oxidative stress and inflammation, with strong evidence supporting its use as a medical countermeasure. However, the abstract notes a need for controlled clinical trials to confirm optimal dosage and efficacy.", "population_specificity": "Iranian veterans exposed to sulphur mustard during the Iran-Iraq War (1980-1988) and various model systems.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:59.388403+00:00"}
{"study_id": 75730, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to highlight the importance of conducting RCTs with novel combination treatments, including those targeting alpha7 nicotinic and NMDA receptors, to develop effective antischizophrenia treatments.", "results_summary": "The abstract does not provide specific results on N-Acetylcysteine but suggests that combination treatments targeting multiple pathophysiological mechanisms may enhance efficacy in schizophrenia.", "population_specificity": "Schizophrenia patients (not explicitly stated but implied by the focus on antischizophrenia treatments).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:00.573293+00:00"}
{"study_id": 75732, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine whether high-dose N-acetylcysteine (600 mg twice daily) has therapeutic effects in Chinese patients with early-stage COPD (GOLD I-II).", "results_summary": "The abstract does not provide results, as the study appears to be ongoing or not yet concluded. The trial is designed to assess effectiveness, safety, and cost-effectiveness of long-term NAC treatment.", "population_specificity": "Chinese patients aged 40-80 years with early-stage COPD (GOLD I-II).", "effective_dosage": "600 mg twice daily", "study_duration": "2 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:00.698900+00:00"}
{"study_id": 75731, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether high-dose N-Acetylcysteine (NAC) could prevent respiratory failure in patients with severe COVID-19 by restoring redox homeostasis.", "results_summary": "The study found no significant difference in the need for mechanical ventilation, ICU admission, ICU stay duration, or mortality between the NAC and placebo groups, indicating NAC did not improve outcomes in severe COVID-19.", "population_specificity": "Patients with severe COVID-19 (confirmed or suspected), oxyhemoglobin saturation <94% or respiratory rate >24 breaths/minute.", "effective_dosage": "21 g (~300 mg/kg) over 20 hours.", "study_duration": "20 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:01.308332+00:00"}
{"study_id": 75733, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine improves autistic behaviors by addressing glutaminergic dysregulation in autism spectrum disorder.", "results_summary": "The meta-analysis of five randomized controlled trials showed improvement in autistic behaviors as measured by the Aberrant Behavior Checklist, Social Responsiveness Scale, and Repetitive Behavior Scale-Revised after 8-12 weeks of N-Acetylcysteine treatment. The results suggest a beneficial effect, though the abstract does not provide detailed statistical outcomes.", "population_specificity": "Individuals with autism spectrum disorder.", "effective_dosage": "Not specified in the abstract.", "study_duration": "8-12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:02.427246+00:00"}
{"study_id": 75734, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers aimed to determine whether n-acetylcysteine maintenance could attenuate alcohol self-administration and its subjective effects in individuals with alcohol use disorder.", "results_summary": "n-Acetylcysteine did not alter the effects of alcohol, including self-administration or subjective responses, indicating it is unlikely to be an effective standalone treatment for alcohol use disorder. However, it was safely combined with alcohol.", "population_specificity": "Nine subjects with alcohol use disorder.", "effective_dosage": "1.2 g and 2.4 g n-acetylcysteine, administered in random order.", "study_duration": "Five days of maintenance per dose, followed by experimental sessions.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:02.719729+00:00"}
{"study_id": 75735, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the current status of N-Acetylcysteine as the only clinically used antidote for acetaminophen-induced liver toxicity and explore potential new therapeutic targets.", "results_summary": "The abstract highlights N-Acetylcysteine as the sole clinically approved antidote for acetaminophen hepatotoxicity but does not provide new efficacy data. It focuses more on emerging alternatives like fomepizole and calmangafodipir.", "population_specificity": "Not specified (general discussion of clinical and preclinical use)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:03.283206+00:00"}
{"study_id": 75736, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine, as an adjunct anti-inflammatory therapy, could enhance tuberculosis treatment outcomes by improving sputum smear conversion rates and radiographic resolution.", "results_summary": "N-Acetylcysteine accelerated radiographic resolution compared to placebo at 8 weeks, suggesting a beneficial effect on TB treatment. No differences in adverse events were observed between N-Acetylcysteine and other treatments.", "population_specificity": "Adults aged 18-70 years receiving antibiotic treatment for pulmonary TB (74.7% male).", "effective_dosage": "Not specified", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:06.329140+00:00"}
{"study_id": 75740, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-acetylcysteine inhalation therapy improves the quality of life in head and neck cancer patients undergoing radiation therapy.", "results_summary": "N-acetylcysteine inhalation reduced painkiller use and improved dry mouth symptoms significantly compared to the control group, with no reported side effects.", "population_specificity": "Head and neck cancer patients receiving radiation therapy.", "effective_dosage": "2400 mg daily via nebulized inhalation.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:08.813317+00:00"}
{"study_id": 75739, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 40, "quality_score": 85, "study_goal": "The researchers aimed to determine whether pre-exposure antioxidant supplementation (including N-Acetylcysteine) could blunt the oxidative stress response induced by diesel exhaust inhalation in healthy adults.", "results_summary": "N-Acetylcysteine pretreatment did not significantly attenuate the oxidative effects (GSH/GSSG ratio) caused by diesel exhaust exposure but appeared to modestly reduce the impact on IL-6 mRNA expression.", "population_specificity": "Nineteen nonsmoking healthy adults", "effective_dosage": "Not specified", "study_duration": "Single 120-minute exposure", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:09.184638+00:00"}
{"study_id": 75738, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to determine if intrapartum N-Acetylcysteine (NAC) administration could reduce prematurity-related morbidity in newborns exposed to intrauterine infection/inflammation (Triple I).", "results_summary": "NAC significantly improved newborn status at birth, reduced the need for intensive resuscitation, and lowered the incidence of severe prematurity-related morbidities, particularly bronchopulmonary dysplasia (BPD). The effects were independent of gestational age, birth weight, sex, or race, and mechanistic data suggested epigenetic involvement.", "population_specificity": "Pregnant women with impending preterm birth due to confirmed Triple I (n=67) and their newborns.", "effective_dosage": "Intravenous infusion mimicking the FDA-approved regimen (exact dosage not specified in abstract).", "study_duration": "Duration of intervention not explicitly stated in abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:10.348292+00:00"}
{"study_id": 75737, "supplement_id": 1364, "safety_score": "70", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the efficacy of intravenous N-Acetylcysteine (NAC) in reducing liver injury recovery time and improving outcomes in hospitalized adult patients with anti-tuberculosis drug-induced liver injury (AT-DILI).", "results_summary": "NAC did not significantly reduce the time for serum ALT to fall below 100 U/L compared to placebo but shortened the median hospital stay (9 vs. 18 days). Mortality rates were similar between groups, though adverse reactions led to early discontinuation in some NAC recipients.", "population_specificity": "Hospitalized adult patients (mean age 38, 57% female, 87% HIV-positive) with AT-DILI.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Median time to ALT <100 U/L was 7.5 days in the NAC arm and 8 days in the placebo arm.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:10.617929+00:00"}
{"study_id": 75742, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to identify characteristics of retinal loci associated with sensitivity changes during NAC treatment in retinitis pigmentosa (RP) patients.", "results_summary": "Higher NAC doses reduced the risk of macular sensitivity loss, with foveal and superior loci more likely to show improvement. Low baseline sensitivity loci were more likely to either decrease or increase in sensitivity.", "population_specificity": "30 patients with retinitis pigmentosa (51 evaluable eyes).", "effective_dosage": "600, 1,200, or 1,800 mg twice daily for 3 months, then three times/day for 3 months.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:11.854192+00:00"}
{"study_id": 75741, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-acetylcysteine (NAC) supplementation affects inflammatory biomarkers in adults by reviewing existing literature.", "results_summary": "Oral NAC supplementation reduced serum levels of CRP and IL-6 but did not significantly affect other inflammatory biomarkers. The study suggests more RCTs are needed to explore dosage and administration route effects.", "population_specificity": "Adults (sample size of 1057 across 24 RCTs).", "effective_dosage": "400 to 2000 mg/d.", "study_duration": "1 to 80 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:12.057891+00:00"}
{"study_id": 75743, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the potential of N-Acetylcysteine (NAC) in attenuating COVID-19 risk and treating severe cases due to its antioxidant and anti-inflammatory properties.", "results_summary": "The study suggests that oral NAC may reduce the risk of developing COVID-19, while high-dose intravenous NAC could serve as an adjuvant treatment for severe cases, mitigating complications like pulmonary and cardiovascular adverse events.", "population_specificity": "COVID-19 patients and those at risk of infection (generalized, not specific).", "effective_dosage": "High-dose intravenous NAC (specific amount not mentioned); oral dosage not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:12.592322+00:00"}
{"study_id": 75744, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 25, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-acetylcysteine as an adjunctive treatment improves symptoms in bipolar depression and major depressive disorder.", "results_summary": "N-acetylcysteine did not significantly improve depressive symptoms compared to placebo but showed a reduction in CGI-S score without specific symptom improvements.", "population_specificity": "Adults with bipolar depression or major depressive disorder (mean age 46.81, 58.45% female).", "effective_dosage": "Not specified", "study_duration": "8-24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:13.952502+00:00"}
{"study_id": 75746, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether dietary supplementation or intravenous administration of N-acetylcysteine could alleviate lung injury and dysfunction caused by viruses and environmental pollutants.", "results_summary": "The study suggests that N-acetylcysteine, among other amino acids, may reduce oxidative stress, inhibit apoptosis, and regulate immune responses, thereby improving lung epithelial barriers and respiratory health. However, specific efficacy data for N-acetylcysteine alone were not detailed.", "population_specificity": "Human patients and animal models with lung injuries or disorders.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:17.298450+00:00"}
{"study_id": 75745, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to confirm the efficacy of N-Acetylcysteine (NAC) as an adjunctive therapy for treatment-resistant PTSD in a larger, double-blind, placebo-controlled trial.", "results_summary": "The study found that NAC significantly reduced PTSD symptoms in veterans compared to placebo in a prior pilot study, and this trial seeks to validate those findings with a larger sample and additional biomarker analysis.", "population_specificity": "Adult patients with treatment-resistant PTSD following first-line treatment.", "effective_dosage": "2.7 g/day (900 mg three times daily) administered orally.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:17.533897+00:00"}
{"study_id": 75748, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the efficacy of N-Acetylcysteine (NAC) in reducing inflammation and oxidative stress through a meta-analysis of existing studies.", "results_summary": "NAC significantly reduced malondialdehyde (MDA), IL-8, and homocysteine levels, with sensitivity analysis showing significant effects on TNF-\u03b1 and IL-6. No significant change was observed in CRP levels.", "population_specificity": "Not specified (meta-analysis of 28 studies).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:18.891004+00:00"}
{"study_id": 75747, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the role of N-Acetylcysteine (NAC) in treating acetaminophen (APAP)-induced hepatotoxicity and its limitations in delayed treatment scenarios.", "results_summary": "NAC, when administered with activated charcoal, is the mainstay therapy for APAP overdose but has limitations in rescuing delayed patients, potentially necessitating liver transplantation. The study highlights the involvement of complex molecular pathways in liver injury and the challenges in NAC's efficacy for late-stage toxicity.", "population_specificity": "Patients with APAP-induced hepatotoxicity (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:19.486029+00:00"}
{"study_id": 75749, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of N-acetylcysteine as an adjunctive treatment for smoking cessation in heavy smokers.", "results_summary": "N-acetylcysteine combined with first-line treatment significantly reduced exhaled carbon monoxide levels but did not significantly affect nicotine withdrawal, depressive symptoms, or metabolic measures compared to placebo. However, it significantly reduced sTNF-R2 levels, suggesting potential anti-inflammatory effects.", "population_specificity": "Heavy smokers with tobacco use disorder (n=34).", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:19.704218+00:00"}
{"study_id": 75751, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to explore emerging pharmacotherapies, including N-acetylcysteine, for the treatment of onychophagia (nail-biting) in pediatric patients.", "results_summary": "The abstract mentions N-acetylcysteine as an emerging pharmacotherapy for onychophagia but does not provide specific efficacy or safety data. It highlights the need for further research on its application in pediatric nail disorders.", "population_specificity": "Pediatric patients with nail disorders, specifically onychophagia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:19.756600+00:00"}
{"study_id": 75750, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and tolerability of combination therapy with pirfenidone plus inhaled N-acetylcysteine versus pirfenidone alone in patients with idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study found that combination therapy with pirfenidone and inhaled N-acetylcysteine resulted in a significantly greater decline in forced vital capacity (FVC) compared to pirfenidone alone, suggesting worse outcomes for IPF patients.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (IPF).", "effective_dosage": "352.4 mg twice daily.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:20.455226+00:00"}
{"study_id": 75752, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the potential of N-Acetylcysteine (NAC) as part of a therapeutic strategy to mitigate oxidative stress and neuroinflammation in Parkinson's disease (PD).", "results_summary": "The study suggests that NAC supplementation may help fortify intracellular glutathione, potentially attenuating oxidative stress and mitochondrial dysfunction in PD. It highlights NAC as part of a broader dietary and nutraceutical approach to neuroprotection.", "population_specificity": "Parkinson's disease patients (clinical and experimental research data reviewed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:22.531998+00:00"}
{"study_id": 75753, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to examine pharmacotherapeutic options, including N-Acetylcysteine, for treating trichotillomania in adults.", "results_summary": "The study found preliminary evidence that N-Acetylcysteine may be effective for trichotillomania, but noted a lack of large controlled trials, suggesting case-by-case decision-making.", "population_specificity": "Adults with trichotillomania, often with comorbid psychiatric diagnoses.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:24.783838+00:00"}
{"study_id": 75754, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 30, "study_goal": "The researchers aimed to explore the potential benefits of N-Acetylcysteine in treating immune thrombotic thrombocytopenic purpura (iTTP) by targeting von Willebrand factor (VWF) and platelet aggregation.", "results_summary": "The abstract mentions that N-Acetylcysteine showed potential benefits in iTTP on a small scale, but lacks robust evidence from larger randomized controlled trials.", "population_specificity": "Patients with immune thrombotic thrombocytopenic purpura (iTTP).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:25.568864+00:00"}
{"study_id": 75759, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to synthesize evidence on the efficacy of N-Acetylcysteine as a pharmacological intervention for stimulant use disorder.", "results_summary": "The study found insufficient evidence to either support or discount the use of N-Acetylcysteine for treating stimulant use disorder, indicating a need for further research.", "population_specificity": "Individuals with stimulant use disorder.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:26.898264+00:00"}
{"study_id": 75756, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effect of N-acetylcysteine (NAC) on the incidence and severity of paclitaxel-induced peripheral neuropathy (PIPN) in breast cancer patients.", "results_summary": "NAC significantly reduced the incidence and severity of PIPN, improved quality of life scores, and showed favorable changes in serum biomarkers (higher NGF and lower MDA levels) compared to the control group. The high-dose NAC group (1200 mg twice daily) demonstrated the most pronounced benefits.", "population_specificity": "Breast cancer patients receiving adjuvant paclitaxel chemotherapy.", "effective_dosage": "1200 mg once daily and 1200 mg twice daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:27.787105+00:00"}
{"study_id": 75758, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 60, "quality_score": 65, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) is safe, well-tolerated, and efficacious as adjunctive therapy for TB in hospitalized HIV patients.", "results_summary": "The study found that NAC was not unsafe and had similar adverse event rates to the control group, with a potential impact on faster negative cultures that requires further investigation.", "population_specificity": "Hospitalized patients over 18 years with HIV-associated pulmonary TB in the Brazilian Amazon.", "effective_dosage": "600 mg twice daily (bid)", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:28.232992+00:00"}
{"study_id": 75757, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to evaluate changes in inflammatory and oxidative stress levels following NAC treatment and assess their potential to predict or moderate clinical outcomes, primarily depression scores.", "results_summary": "The study found no significant changes in IL-6 or TAC levels after 16 weeks of NAC treatment. However, baseline IL-6 levels moderated treatment response in the mitochondrial-enhancing agents group, but not specifically for NAC.", "population_specificity": "Participants in a placebo-controlled randomized trial (n = 163), likely with depression (based on MADRS and CGI-I outcomes).", "effective_dosage": "Not specified", "study_duration": "16 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:29.293756+00:00"}
{"study_id": 75760, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) could prevent serious adverse events, including cardiac complications, in transfusion-dependent thalassemia (TDT) patients by reducing oxidative stress and balancing cardiac sympathovagal control.", "results_summary": "NAC significantly reduced serious adverse events (3.3% vs. 24.1% in controls) and improved heart rate variability (HRV) but did not demonstrate a difference in cardiac complications. The proposed mechanism was balancing sympathovagal control.", "population_specificity": "59 Thai transfusion-dependent thalassemia (TDT) patients.", "effective_dosage": "600 mg orally daily.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:30.036026+00:00"}
{"study_id": 75761, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to determine when N-acetylcysteine treatment is indicated for pediatric cases of paracetamol overdose and how to assess its necessity.", "results_summary": "The study found that N-acetylcysteine treatment should be initiated based on the worst-case exposure amount and time elapsed since ingestion. It emphasized the importance of timely assessment to prevent severe hepatotoxicity.", "population_specificity": "Pediatric and adolescent patients presenting with paracetamol overdose in emergency departments.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:30.574723+00:00"}
{"study_id": 75765, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effect of an antioxidant dressing containing N-Acetylcysteine on chronic wound healing against a standard wound dressing in patients with hard-to-heal wounds.", "results_summary": "The study evaluates the efficacy of an antioxidant dressing combining N-Acetylcysteine and curcumin, focusing on wound reactivation and healing in chronic wounds, but specific results regarding N-Acetylcysteine alone are not detailed in the abstract.", "population_specificity": "Patients with hard-to-heal wounds from three primary public health care centres in Andaluc\u00eda, Spain.", "effective_dosage": "Not specified", "study_duration": "8 weeks or until complete healing if earlier", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:37.125740+00:00"}
{"study_id": 75763, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the role of N-Acetylcysteine as an adjuvant therapy in improving survival for patients with severe alcoholic hepatitis.", "results_summary": "The study suggests N-Acetylcysteine can be an adjuvant therapy with a positive impact on patient survival, though specific efficacy data are not detailed. It is grouped with other potential adjuvant treatments like granulocyte-colony stimulating factor and metadoxine.", "population_specificity": "Patients with severe alcoholic hepatitis (modified Maddrey's discriminant function score \u2265 32 or MELD score \u2265 21).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:37.435626+00:00"}
{"study_id": 75764, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to explore the potential of N-Acetylcysteine as a pharmacological treatment for trichotillomania (TTM) based on its glutamate-modulating properties.", "results_summary": "The abstract suggests that N-Acetylcysteine, among other glutamate-modulating agents, shows promise as a newer pharmacotherapy option for TTM, though evidence of benefit varies and side effect profiles of other treatments limit their utility.", "population_specificity": "Individuals with trichotillomania (TTM).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:38.876617+00:00"}
{"study_id": 75768, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and efficacy of combining N-acetylcysteine (NAC) with pirfenidone (PFD) compared to PFD alone in treating idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study found that combining NAC with PFD did not significantly alter pulmonary function decline or side effect rates compared to PFD alone, suggesting no added benefit or harm from the combination.", "population_specificity": "IPF patients (total n=319 across 6 studies).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Up to 24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:39.009494+00:00"}
{"study_id": 75769, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effectiveness of a transtympanic approach, including N-acetylcysteine, as an otoprotectant strategy against cisplatin-induced hearing loss.", "results_summary": "The study reviewed clinical trials using N-acetylcysteine as an otoprotectant via transtympanic injection, noting its potential to limit side effects and avoid interactions with cisplatin, but highlighted unresolved issues such as optimal dosage and injection frequency.", "population_specificity": "Patients undergoing cisplatin chemotherapy (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:39.152213+00:00"}
{"study_id": 75766, "supplement_id": 1364, "safety_score": "93", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to assess the effectiveness and safety of N-Acetylcysteine (NAC) in treating rodenticide poisoning, given the lack of a definitive antidote and high mortality rates.", "results_summary": "The study found that NAC significantly improved survival rates in rodenticide poisoning cases (p \u2264 0.03) and had a good safety profile, with 93.4% of participants experiencing no adverse effects. Yellow Phosphorus poisoning and a time lag of \u226524 hours were identified as significant risk factors for mortality.", "population_specificity": "Patients admitted to a tertiary care teaching hospital in rural India with rodenticide poisoning (mean age 30.04 \u00b1 15.67 years, 86% suicidal intent).", "effective_dosage": "Mean oral loading dose of 7580.95 \u00b1 2204.29 mg and maintenance dose of 3694.53 \u00b1 2322.58 mg.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:39.433089+00:00"}
{"study_id": 75767, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy of N-acetylcysteine in reducing symptoms of trichotillomania compared to placebo.", "results_summary": "N-acetylcysteine demonstrated a significant benefit in reducing trichotillomania symptoms compared to placebo, with a standardized mean difference of -0.75 (95% CI: -1.36, -0.13, p = 0.017). The effect size was moderate, suggesting clinical relevance.", "population_specificity": "Individuals with trichotillomania (hair-pulling disorder).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:39.568999+00:00"}
{"study_id": 75771, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the potential of N-Acetylcysteine as an antioxidant treatment for COPD by addressing oxidative stress mechanisms.", "results_summary": "N-Acetylcysteine, along with other glutathione-generating antioxidants, was found to reduce exacerbations in COPD patients, though it remains unclear whether this effect is due to antioxidant or mucolytic properties. Dietary antioxidants were not clinically effective in COPD.", "population_specificity": "COPD patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:45.367534+00:00"}
{"study_id": 75762, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate whether N-acetylcysteine (NAC) could prevent vancomycin-induced nephrotoxicity (VIN) by acting as an antioxidant.", "results_summary": "NAC significantly improved kidney function markers (lower serum creatinine, higher creatinine clearance) compared to the control group. Although not statistically significant, fewer cases of acute kidney injury occurred in the NAC group (4.76% vs. 12.63%).", "population_specificity": "Patients receiving vancomycin for any indication.", "effective_dosage": "600 mg orally every 12 hours.", "study_duration": "10 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:46.066945+00:00"}
{"study_id": 75776, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not specifically address N-Acetylcysteine; it focuses on ferroptosis and its implications in neurological diseases.", "results_summary": "The abstract does not discuss N-Acetylcysteine or its effects.", "population_specificity": "Not specified (abstract discusses ferroptosis broadly).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:46.345012+00:00"}
{"study_id": 75774, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on N-Acetylcysteine but rather reviews the pharmacological potential and toxicological aspects of Vanadium (V) and its interactions with Magnesium (Mg).", "results_summary": "The study does not report any findings related to N-Acetylcysteine.", "population_specificity": "Not applicable (study does not involve N-Acetylcysteine).", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:46.420011+00:00"}
{"study_id": 75772, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to analyze positive and negative sentiments regarding symptoms and treatment effects post N-acetylcysteine (NAC) administration in individuals with RYR1-RM.", "results_summary": "The study found that NAC group participants reported more positive comments regarding treatment effects compared to the placebo group, with a greater number of positive comments post-intervention. Fatigue and weakness were highlighted as key symptoms.", "population_specificity": "Individuals with ryanodine receptor 1-related myopathies (RYR1-RM).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:46.436417+00:00"}
{"study_id": 75773, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "To investigate whether combined antioxidant therapy (N-acetylcysteine, vitamin E, and vitamin C) reduces migraine frequency and severity in adults.", "results_summary": "The study found that the combined antioxidant therapy significantly reduced monthly headache and migraine frequency, migraine duration, pain scores, and acute medication use compared to sham treatment. However, the difference between the two groups was not statistically significant for the primary outcome.", "population_specificity": "Adults reporting 2 to 8 migraines per month for at least a year.", "effective_dosage": "Not specified", "study_duration": "3 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:47.962054+00:00"}
{"study_id": 75775, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine, among other interventions, could mitigate perioperative acute kidney injury (AKI) by targeting inflammation or oxidative stress.", "results_summary": "The study found that N-Acetylcysteine, along with other interventions targeting inflammation or oxidative stress, did not show renal benefits in perioperative settings. High-dose perioperative statin treatment even increased AKI in some patient groups.", "population_specificity": "Adult patients undergoing surgery (100 or more per trial).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:48.040552+00:00"}
{"study_id": 75778, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine as a penetration enhancer for topical drug delivery in treating onychomycosis.", "results_summary": "N-Acetylcysteine was identified as one of several penetration enhancers that improved drug delivery across the nail plate, though the abstract does not provide specific efficacy data for N-Acetylcysteine alone. The study highlights the need for improved topical therapies due to poor nail plate penetration.", "population_specificity": "Individuals with onychomycosis (nail fungal infections).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:48.249499+00:00"}
{"study_id": 75779, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether NAC maintenance reduces cocaine-seeking behavior in cocaine-dependent individuals during both cocaine-primed and unprimed self-administration sessions.", "results_summary": "The study examined NAC's effects on cocaine-seeking behavior in a crossover design, but the abstract does not specify the outcomes. A subset of participants underwent neurochemical assessments in the rostral anterior cingulate.", "population_specificity": "Non-treatment-seeking, cocaine-dependent individuals (n = 12).", "effective_dosage": "1200 mg TID (3600 mg/day total).", "study_duration": "1 week per condition (NAC and placebo).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:53.933715+00:00"}
{"study_id": 75781, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to summarize existing data on the effectiveness of antioxidants, including N-Acetylcysteine, in providing cardiovascular protection in end-stage renal disease patients.", "results_summary": "The abstract does not provide specific results for N-Acetylcysteine but suggests oxidative stress plays a role in cardiovascular disease in this population, and antioxidants may counteract these effects.", "population_specificity": "End-stage renal disease patients", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:54.006304+00:00"}
{"study_id": 75780, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to evaluate N-Acetylcysteine's potential antiepileptogenic or disease-modifying effects in preventing or modifying post-injury epilepsy.", "results_summary": "The study mentions N-Acetylcysteine as one of several medications with antiepileptogenic or disease-modifying effects in animal models, but lacks detailed results specific to its efficacy or mechanisms.", "population_specificity": "Animal models of acquired epilepsy (e.g., post-traumatic brain injury or cerebrovascular accidents).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:54.708061+00:00"}
{"study_id": 75782, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine, among other medications, is effective in treating restricted/repetitive behaviors in Autism Spectrum Disorder.", "results_summary": "The meta-analysis found no significant difference between N-Acetylcysteine and placebo in treating restricted/repetitive behaviors in ASD. The overall analysis, including other medications, also showed no significant benefit over placebo.", "population_specificity": "Patients with Autism Spectrum Disorder of all ages.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:54.866755+00:00"}
{"study_id": 75783, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine, in combination with isotonic saline, could prevent contrast-induced nephropathy (CIN) in chronic kidney disease (CKD) patients undergoing coronary angiography.", "results_summary": "The study found no statistically significant difference in eGFR reduction between the group receiving N-Acetylcysteine plus isotonic saline and the group receiving isotonic saline alone, indicating no additive benefit of N-Acetylcysteine in CIN prevention. CIN did not develop in any group, but eGFR significantly decreased in all groups post-angiography.", "population_specificity": "CKD patients (eGFR < 60 cc/min) undergoing coronary angiography.", "effective_dosage": "1200mg twice a day for 2 days.", "study_duration": "2 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:56.296321+00:00"}
{"study_id": 75785, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of N-acetylcysteine in detoxifying arecoline N-oxide and its role in preventing carcinogenesis related to betel quid and areca nut use.", "results_summary": "N-acetylcysteine was found to detoxify arecoline N-oxide, a carcinogenic metabolite of areca nut, and may help treat oral potentially malignant disorders by addressing reactive oxygen species involved in carcinogenesis pathways.", "population_specificity": "High-risk groups for oral cancer, particularly betel quid and areca nut users.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:56.438090+00:00"}
{"study_id": 75786, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine (NAC) in treating early-stage APAP-induced liver injury and compare it to mesenchymal stem cell (MSC) therapies for late-stage injury.", "results_summary": "NAC effectively restores liver functions early after APAP intake but does not protect against APAP-induced injury at the late stage. MSC-based therapies show promise for promoting liver regeneration and injury repair in both early and late stages.", "population_specificity": "APAP overdose-treated animals and patients (not further specified).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:57.341166+00:00"}
{"study_id": 75784, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers examined whether statin pretreatment, including cases where N-acetylcysteine was used, reduced the risk of contrast-induced acute kidney injury (CI-AKI) in patients with renal insufficiency.", "results_summary": "The study found that statin pretreatment significantly reduced the risk of CI-AKI, and this effect was consistent regardless of N-acetylcysteine use. However, the abstract does not isolate N-acetylcysteine's independent efficacy.", "population_specificity": "Patients with mild to moderate renal insufficiency (baseline eGFR <60 mL/min/1.73 m\u00b2 or 30 < eGFR < 90 mL/min/1.73 m\u00b2).", "effective_dosage": "Not specified for N-acetylcysteine.", "study_duration": "Short-term (specific duration not mentioned).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:58.556908+00:00"}
{"study_id": 75788, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 70, "quality_score": 90, "study_goal": "The researchers aimed to test the efficacy of N-acetylcysteine (NAC) in reducing alcohol use and PTSD symptoms in adults with co-occurring AUD and PTSD.", "results_summary": "The abstract does not provide specific results, but it describes the study design and rationale for using NAC to modulate glutamate and potentially improve outcomes for AUD/PTSD.", "population_specificity": "Adults with co-occurring alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD).", "effective_dosage": "2400 mg/day", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:02.383833+00:00"}
{"study_id": 75787, "supplement_id": 1364, "safety_score": "30", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to examine associations between commonly used drugs, including N-Acetylcysteine (NAC), and mortality in COPD patients.", "results_summary": "The study found that NAC use was dose-dependently associated with an increased risk of death in COPD patients (HR: 1.26, 95% CI: 1.08-1.48).", "population_specificity": "Swedish primary care patients with physician-diagnosed COPD.", "effective_dosage": "Not specified", "study_duration": "Observational period from 1999-2009", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:02.736834+00:00"}
{"study_id": 75790, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether N-acetylcysteine could reduce or delay oxaliplatin-induced neuropathy in patients with gastric or colorectal cancers.", "results_summary": "The study found that N-acetylcysteine significantly reduced neuropathy severity compared to placebo, as measured by the NCI-CTCAE scale, and delayed its occurrence in patients undergoing oxaliplatin-based chemotherapy.", "population_specificity": "Patients with colorectal or gastric cancer receiving oxaliplatin in the XELOX regimen.", "effective_dosage": "Two 600 mg tablets administered 1 hour before oxaliplatin infusion.", "study_duration": "Eight courses of chemotherapy.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:03.538190+00:00"}
{"study_id": 75789, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to explore the role of MMP-9 in ocular surface diseases and identify potential therapeutic interventions, including N-Acetylcysteine (NaC), to modulate its overexpression.", "results_summary": "The study found that N-Acetylcysteine (NaC) is among the molecular factors that blunt MMP-9 expression, suggesting its potential therapeutic role in improving ocular surface diseases mediated by MMP-9 overexpression. Inhibition of MMP-9, including by NaC, frequently led to improvement in ocular surface disease states.", "population_specificity": "Not specified (in vitro and in vivo models of ocular surface diseases).", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:03.904675+00:00"}
{"study_id": 75794, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 50, "study_goal": "The researchers aimed to evaluate the potential benefits of N-acetylcysteine supplementation combined with a valine-restricted diet in improving the prognosis of patients with SCEH deficiency.", "results_summary": "The study found that early intervention with a valine-restricted diet and N-acetylcysteine supplementation could improve the prognosis of patients with SCEH deficiency, as suggested by clinical observations in two cases.", "population_specificity": "Patients with SCEH deficiency (a rare congenital metabolic disorder) presenting in infancy or early childhood.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:06.300319+00:00"}
{"study_id": 75791, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) could prevent ischemic hepatitis (IH) and improve outcomes in cirrhotic patients with acute variceal bleed (AVB).", "results_summary": "NAC reduced the incidence of IH and acute kidney injury (AKI) and lowered deaths due to liver failure at 6 weeks compared to standard care alone. The study found statistically significant benefits in preventing IH and improving survival.", "population_specificity": "Cirrhotic patients with acute variceal bleed.", "effective_dosage": "150 mg/kg/h for 1 h, followed by 12.5 mg/kg/h for 4 h, then 6.25 mg/kg/h for 67 h.", "study_duration": "72 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:06.320189+00:00"}
{"study_id": 75792, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the effect of oral N-acetylcysteine (NAC) supplementation on immune system biomarkers (HsCRP, MPO, and Gal-3) in acute myocardial infarction (AMI) patients receiving fibrinolytic therapy.", "results_summary": "NAC supplementation significantly reduced HsCRP, MPO, and Gal-3 levels in AMI patients after 72 hours compared to the control group, with statistically significant intergroup and intragroup differences. The control group did not show these reductions.", "population_specificity": "32 AMI patients with ST segment elevation (STEMI) receiving fibrinolytic therapy.", "effective_dosage": "600 mg every 8 hours (3 times daily).", "study_duration": "3 consecutive days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:07.772393+00:00"}
{"study_id": 75795, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to review the pharmacological and toxicological findings of acetaminophen (APAP), including the role of N-Acetylcysteine in mitigating APAP-induced hepatotoxicity.", "results_summary": "The study found that N-Acetylcysteine is the only effective treatment for APAP-induced acute liver failure, though the precise mechanisms of APAP hepatotoxicity (e.g., JNK pathway activation, ER stress, mitochondrial oxidative stress) remain unclear.", "population_specificity": "General population, with implications for high-risk groups (elderly, children, pregnant women).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:08.198634+00:00"}
{"study_id": 75796, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine as a preventive strategy for contrast-induced acute kidney injury (CI-AKI) in patients undergoing procedures requiring iodinated contrast injection.", "results_summary": "The study found that N-Acetylcysteine, along with other strategies like bicarbonate and ACE inhibitor withdrawal, failed to demonstrate clear benefits in preventing CI-AKI in randomized trials, leading to discouragement of its use in clinical practice. Effective strategies included hydration, contrast volume reduction, and statin use.", "population_specificity": "Patients undergoing percutaneous coronary interventions (PCI) or other procedures requiring iodinated contrast injection.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:11.247043+00:00"}
{"study_id": 75797, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to investigate the efficacy of N-Acetylcysteine (NAC) in reducing oxidative stress (measured by urine 15-F2t isoprostane) and improving physical function (measured by 6-minute walk test distance) in a specific population.", "results_summary": "The study found that participants had elevated baseline oxidative stress and reduced physical function compared to the general population. NAC treatment showed some improvement in these measures, though the abstract does not provide detailed statistical outcomes.", "population_specificity": "Ambulatory individuals with elevated oxidative stress and reduced physical function (n = 33, with 16 receiving NAC and 17 placebo).", "effective_dosage": "Adult dose 2,700 mg/day; pediatric dose 30 mg/kg/day.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:13.404921+00:00"}
{"study_id": 75799, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers examined whether N-Acetylcysteine could mimic the effects of Mucidosphaerium sp. (MS) in reducing oxidative stress, RAGE gene expression, and lipid accumulation in adipocytes.", "results_summary": "N-Acetylcysteine replicated MS's effects by reducing ROS generation, RAGE gene expression, and lipid accumulation in differentiated adipocytes, suggesting its potential role in mitigating insulin resistance via the AGE-RAGE-oxidative stress axis.", "population_specificity": "Overweight subjects (human trial) and fructose-fed rats (animal study).", "effective_dosage": "Not specified", "study_duration": "Not specified for N-Acetylcysteine (MS was administered for 8 weeks in rats and 12 weeks in humans).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:13.405280+00:00"}
{"study_id": 75798, "supplement_id": 1364, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of N-Acetylcysteine (NAC) as an antidote for acetaminophen (APAP) overdose and explore potential alternative treatments.", "results_summary": "NAC was found to effectively promote hepatic GSH recovery, scavenge reactive metabolites, and support mitochondrial bioenergetics, but it has side effects and may not be effective after high overdoses. Alternative drugs like 4-methylpyrazole and calmangafodipir show promise as complementary or alternative antidotes.", "population_specificity": "Patients with acetaminophen-induced liver injury or acute liver failure (primarily in western countries).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:14.894652+00:00"}
{"study_id": 75802, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether inhaled N-acetylcysteine (NAC) had additive effects for treating laryngopharyngeal reflux disease (LPRD) when used alongside proton pump inhibitors (PPIs).", "results_summary": "The study found no significant overall difference in outcomes between patients treated with NAC plus PPI versus PPI alone. However, NAC showed late additional therapeutic effects in patients with poor early response to PPI treatment.", "population_specificity": "Patients with reflux symptom index (RSI) >13 and reflux finding scores (RFS) >7.", "effective_dosage": "Not specified", "study_duration": "2 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:16.682504+00:00"}
{"study_id": 75803, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers aimed to assess the clinical effect of N-Acetylcysteine (NAC) on pulmonary function in patients with diffuse scleroderma.", "results_summary": "The study found no significant differences in plethysmography parameters between NAC and placebo groups after 24 weeks. However, NAC did not prevent a significant decline in DLCO observed in the placebo group, suggesting it had no effect versus placebo.", "population_specificity": "25 patients with diffuse systemic sclerosis (SSc) without initial lung involvement.", "effective_dosage": "1200 milligrams of NAC.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:16.761228+00:00"}
{"study_id": 75801, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to examine whether N-acetylcysteine, combined with vitamin C, could reduce myocardial injury in high-risk patients undergoing non-cardiac surgery by scavenging reactive oxygen species.", "results_summary": "The abstract does not provide specific results regarding N-acetylcysteine's effects, as the study is ongoing (VIXIE trial). The primary outcome will measure troponin release as a marker of myocardial injury.", "population_specificity": "600 patients with cardiovascular risk factors undergoing major non-cardiac surgery.", "effective_dosage": "Intravenous infusion of N-acetylcysteine (specific dosage not mentioned).", "study_duration": "Administered during and for 2 hours after surgery.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:16.879587+00:00"}
{"study_id": 75804, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine as an adjunctive treatment in a specific medical context.", "results_summary": "The study concluded that evidence supports the notion that N-Acetylcysteine has beneficial effects, though the abstract does not specify the exact outcomes. Seven studies were included in the analysis.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:18.665145+00:00"}
{"study_id": 75807, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to identify changes in resting-state functional connectivity (rs-FC) after a single dose of NAC in schizophrenia patients and examine whether these changes were mediated by glutamate metabolites in the anterior cingulate cortex.", "results_summary": "NAC reduced rs-FC within the default mode and salience networks, specifically between the medial prefrontal cortex to mid frontal gyrus and ACC to frontal pole. No significant correlations were found between ACC glutamate levels and rs-FC changes.", "population_specificity": "20 patients with schizophrenia", "effective_dosage": "2400 mg (single dose)", "study_duration": "Single administration, with MRI scans 7 days apart", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:22.873388+00:00"}
{"study_id": 75805, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to test the safety, tolerability, and effects of oral N-Acetylcysteine (NAC) on visual function in patients with retinitis pigmentosa (RP).", "results_summary": "NAC was safe and well tolerated, with gastrointestinal adverse events resolving spontaneously or with dose reduction. Visual acuity improved significantly in all cohorts, while macular sensitivity improved only in the highest dosage cohort (1800 mg bid). No significant change in ellipsoid zone width was observed.", "population_specificity": "Patients with moderately advanced retinitis pigmentosa (RP).", "effective_dosage": "600 mg, 1200 mg, or 1800 mg twice daily (bid) for 12 weeks, then three times daily (tid) for 12 weeks.", "study_duration": "24 weeks (12 weeks bid + 12 weeks tid).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:24.037003+00:00"}
{"study_id": 75810, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the potential of N-Acetylcysteine in treating encapsulating peritoneal sclerosis (EPS) based on animal study results.", "results_summary": "The abstract mentions that N-Acetylcysteine, among other treatments, yielded promising results in animal studies for EPS, though specific outcomes or statistical significance are not detailed.", "population_specificity": "Animal models (specific species not mentioned).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:24.316903+00:00"}
{"study_id": 75809, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the relationship between physical activity, a nutraceutical \"mitochondrial cocktail\" (which may include N-Acetylcysteine), and clinical outcomes in bipolar depression.", "results_summary": "The study found that participants who engaged in more physical activity and received the combination treatment were more likely to experience a reduction in bipolar depression symptoms, though the direct effects of N-Acetylcysteine alone were not isolated.", "population_specificity": "Individuals with bipolar depression.", "effective_dosage": "Not specified.", "study_duration": "Up to 20 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:24.956364+00:00"}
{"study_id": 75808, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the efficacy of adjunctive N-Acetylcysteine (NAC) in improving psychiatric symptoms in young people with first-episode psychosis (FEP) and explore its neurobiological mechanisms.", "results_summary": "The study is a randomized controlled trial assessing NAC's effects on symptoms, functioning, and neurobiological markers in FEP, with results pending at the time of the abstract. Previous studies suggest NAC reduces negative symptoms and improves functioning in chronic schizophrenia and bipolar disorder.", "population_specificity": "Young people aged 15-25 years with first-episode psychosis, treated at the Early Psychosis Prevention and Intervention Centre in Melbourne, Australia.", "effective_dosage": "2 g/day", "study_duration": "26 weeks (with a 26-week non-treatment follow-up)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:25.112178+00:00"}
{"study_id": 75811, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the therapeutic potential of intravenous N-acetylcysteine (NAC) followed by/or oral ramipril in limiting myocardial injury and accelerating recovery in Takotsubo Syndrome (TTS).", "results_summary": "The study is assessing NAC's effects on myocardial edema resolution, LV systolic function improvement, quality of life, and inflammatory markers, but definitive results are pending as it is a prospective trial.", "population_specificity": "Patients with Takotsubo Syndrome (TTS).", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:25.228645+00:00"}
{"study_id": 75812, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 10, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine as a prophylactic method for contrast-induced acute kidney injury.", "results_summary": "The study found that N-Acetylcysteine is ineffective for preventing contrast-induced acute kidney injury and its use should be abandoned.", "population_specificity": "High-risk patients for contrast-induced acute kidney injury.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:26.112588+00:00"}
{"study_id": 75813, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) reduced depressive symptoms in adults with cannabis use disorder (CUD) and whether its effect on cannabis cessation varied based on baseline depression levels.", "results_summary": "The study found no difference in depressive symptoms between NAC and placebo groups, and NAC did not significantly improve cannabis abstinence. Higher baseline depression was associated with decreased abstinence, particularly in females, and depressive symptoms preceded increased cannabis use, but not vice versa.", "population_specificity": "Adults aged 18-50 with cannabis use disorder (N=302).", "effective_dosage": "2400 mg daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:31.823060+00:00"}
{"study_id": 75814, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to explore neural circuit changes following an 8-week trial of NAC in female adolescents with NSSI and assess its potential as a treatment.", "results_summary": "Reduction in NSSI frequency was associated with changes in amygdala and nucleus accumbens connectivity, suggesting NAC may modulate these circuits. Clinical improvements in depression and global psychopathology were also observed.", "population_specificity": "Female adolescents with non-suicidal self-injury (NSSI).", "effective_dosage": "Not specified", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:31.982346+00:00"}
{"study_id": 75816, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to explore the potential neuroprotective effects of N-acetylcysteine in neonatal encephalopathy caused by perinatal asphyxia.", "results_summary": "The study suggests N-acetylcysteine has potential neuroprotective effects in perinatal asphyxia, but further evidence is needed before it can be implemented as standard care.", "population_specificity": "Term neonates with neonatal encephalopathy due to perinatal asphyxia.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:32.530102+00:00"}
{"study_id": 75815, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 65, "study_goal": "The researchers aimed to explore the relationships between diet quality, dietary inflammatory potential, body mass index, and outcomes of a nutraceutical treatment (including N-Acetylcysteine) for bipolar depression.", "results_summary": "The study found no significant prediction of depression score changes by diet quality, inflammatory index, or BMI in participants taking combination treatment (including N-Acetylcysteine) versus placebo. However, better diet quality was associated with reduced general and bipolar depression symptoms.", "population_specificity": "Participants with bipolar depression.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:33.267902+00:00"}
{"study_id": 75817, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy of N-Acetylcysteine and other redox-active drugs in activating NRF2 and increasing frataxin expression in fibroblasts from FRDA patients.", "results_summary": "N-Acetylcysteine consistently increased NRF2 expression, but its downstream gene activation profile differed from other tested drugs. The abstract does not specify its comparative efficacy relative to other drugs like Sulforaphane.", "population_specificity": "Fibroblasts obtained from skin biopsies of Friedreich's Ataxia (FRDA) patients.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:33.847700+00:00"}
{"study_id": 75818, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the potential of N-Acetylcysteine as an augmentative treatment for obsessive-compulsive disorder (OCD) in cases where standard therapies were inadequate.", "results_summary": "The study identified N-Acetylcysteine as a potential augmentative agent for OCD treatment, alongside other glutamatergic, serotonergic, and anti-inflammatory options, when initial SSRI trials failed. However, specific efficacy data for N-Acetylcysteine were not detailed in the abstract.", "population_specificity": "Patients with treatment-refractory obsessive-compulsive disorder.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:35.627725+00:00"}
{"study_id": 75819, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to determine the effectiveness and safety of N-Acetylcysteine (NAC) in reducing symptoms and exacerbations in patients with chronic bronchitis (CB).", "results_summary": "The meta-analysis found that NAC significantly reduced the frequency of CB exacerbations and improved symptoms compared to placebo, without increasing adverse effects. The pooled relative risk for exacerbations was 0.81 (95% CI 0.69-0.93), and for symptom improvement, it was 1.68 (95% CI 1.13-2.52).", "population_specificity": "Patients with chronic bronchitis (775 in the NAC group, 789 in the placebo group).", "effective_dosage": "Low dosage (<1200 mg per day).", "study_duration": "At least 3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:36.280154+00:00"}
{"study_id": 75800, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the role of N-Acetylcysteine in inhibiting mTOR pathway activation and its clinical efficacy in autoimmune diseases.", "results_summary": "The study found that N-Acetylcysteine, along with rapamycin, showed clinical efficacy in mouse models and clinical trials for autoimmune diseases like systemic lupus erythematosus by blocking mTOR activity and reducing inflammation.", "population_specificity": "Mouse models and clinical trials involving autoimmune diseases (e.g., systemic lupus erythematosus).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:36.823183+00:00"}
{"study_id": 75820, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the protective effects of N-Acetylcysteine (NAC) against T-2 toxin-induced neurotoxicity, focusing on oxidative stress and mitochondrial dysfunction.", "results_summary": "NAC, along with other antioxidants, was shown to provide a protective effect against T-2 toxin-induced oxidative stress, mitochondrial dysfunction, and neuronal cell death by mitigating ROS production and supporting mitochondrial function.", "population_specificity": "In vitro and animal models (specific species not mentioned).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:40.039139+00:00"}
{"study_id": 75821, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 85, "study_goal": "The researchers aimed to evaluate whether oral N-acetylcysteine could prevent major adverse kidney events and death (MAKE-D) and contrast-associated acute kidney injury (CA-AKI) in patients with chronic kidney disease undergoing angiography.", "results_summary": "The study found that preangiography levels of certain biomarkers modestly predicted MAKE-D, but N-acetylcysteine's specific efficacy was not highlighted in the abstract. Biomarker screening could improve future trial efficiency by reducing required sample sizes.", "population_specificity": "Patients with chronic kidney disease undergoing angiography.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:41.026359+00:00"}
{"study_id": 75823, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness of N-acetylcysteine (NAC) as an anti-craving aid for smoking cessation, comparing its impact on sustained abstinence and relapse rates against a placebo.", "results_summary": "The abstract does not provide results, as it describes a planned trial protocol rather than completed findings.", "population_specificity": "Current smokers consuming at least 10 cigarettes per day (n=120).", "effective_dosage": "1.8 g/day of NAC.", "study_duration": "16 weeks of treatment with a 42-week post-discontinuation follow-up.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:41.878855+00:00"}
{"study_id": 75822, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to explore potential therapeutic options, including N-Acetylcysteine, targeting inflammatory, oxidative, and mitochondrial dysfunction pathways in ME/CFS patients.", "results_summary": "The abstract does not provide specific findings on N-Acetylcysteine's effects, only mentioning it as a potential therapeutic option among others.", "population_specificity": "Subgroup of ME/CFS patients diagnosed using the Fukuda criteria.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:42.003259+00:00"}
{"study_id": 75826, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 90, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy of N-Acetylcysteine (NAC) in reducing symptom severity in schizophrenia, particularly in first-episode psychosis or early-phase schizophrenia.", "results_summary": "NAC showed a significant effect size (ES: 1.00; n = 442; CI 0.60-1.41) in reducing symptom severity, with larger positive effects observed in first-episode psychosis or early-phase schizophrenia studies.", "population_specificity": "Patients with schizophrenia, particularly those with first-episode psychosis or early-phase schizophrenia.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:44.916591+00:00"}
{"study_id": 75825, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to review the pharmacology, mode of action, and use of N-Acetylcysteine (NAC) in treating body-focused repetitive behavior disorders like trichotillomania, skin-picking disorders, and onychotillomania.", "results_summary": "The abstract indicates that NAC is a newer treatment modality for these disorders, but it does not provide specific efficacy data or outcomes from the reviewed studies. The focus is on summarizing current research and literature.", "population_specificity": "Patients with body-focused repetitive behavior disorders (e.g., trichotillomania, skin-picking disorders, onychotillomania).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:45.121087+00:00"}
{"study_id": 75824, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of N-acetylcysteine (NAC) in combination with metformin (MTF) and/or ursodeoxycholic acid (UDCA) for treating non-alcoholic steatohepatitis (NASH).", "results_summary": "The study found that NAC + MTF significantly improved steatosis degree, ballooning, and NAFLD Activity Score (NAS), as well as ALT levels, but no significant changes in liver fibrosis were observed in any group. No significant differences were found between the three treatment groups after 48 weeks.", "population_specificity": "Patients with biopsy-proven NASH (median age \u00b154, 32.1% male).", "effective_dosage": "NAC (1.2 g daily) + MTF (850-1500 mg/day) or NAC (1.2 g daily) + UDCA (15 mg/kg) + MTF (850-1500 mg/day).", "study_duration": "48 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:45.186684+00:00"}
{"study_id": 75828, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "To determine if N-acetylcysteine rinse is safe and effective for improving thickened secretions and dry mouth during and after radiotherapy.", "results_summary": "N-acetylcysteine showed potential efficacy in improving sticky saliva and xerostomia, with multiple secondary endpoints favoring it over placebo. The rinse was safe and well-tolerated, though taste was a major dissatisfier.", "population_specificity": "Adult patients (age \u226518 years) undergoing chemoradiotherapy (\u226560 Gy).", "effective_dosage": "10% N-acetylcysteine (2500 mg daily), 5 times daily.", "study_duration": "During radiotherapy and 2 weeks postradiotherapy.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:45.864196+00:00"}
{"study_id": 75829, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 45, "quality_score": 75, "study_goal": "The researchers aimed to investigate the efficacy and tolerability of perioperative intravenous N-acetylcysteine (NAC) as an antioxidant and anti-inflammatory agent in patients undergoing colon surgery.", "results_summary": "NAC administration was safe with only mild side effects in 6.6% of patients, but its efficacy as an antioxidant and anti-inflammatory agent was not statistically significant, showing no meaningful differences in key biomarkers compared to the control group.", "population_specificity": "60 patients admitted to the ICU following colon surgery, requiring parenteral nutrition for at least 5 days.", "effective_dosage": "Loading dose followed by continuous infusion started one hour prior to induction and continued over 48 hours (specific dosage not detailed).", "study_duration": "48 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:49.589829+00:00"}
{"study_id": 75830, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to investigate the potential synergy of N-Acetylcysteine (NAC) with colistin against S. maltophilia isolates and its role in restoring oxidant injury in IPF.", "results_summary": "NAC showed in vitro synergy with colistin against S. maltophilia, suggesting a beneficial role in restoring oxidant injury, likely due to its antioxidant effect. The study also highlights the potential of combining antibacterial and antioxidant therapies for IPF treatment.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (IPF) and chronic lung disease colonized by S. maltophilia.", "effective_dosage": "Concentrations possibly achievable by nebulization (specific dosage not provided).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:50.739562+00:00"}
{"study_id": 75831, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine reduces mortality or improves outcomes like mechanical ventilation duration in adults with ARDS.", "results_summary": "The study found very low-certainty evidence that N-Acetylcysteine may have little or no effect on early mortality (RR 0.64, 95% CI 0.32 to 1.30), but no data were available for other outcomes like late mortality, mechanical ventilation duration, or adverse events.", "population_specificity": "Adults with acute respiratory distress syndrome (ARDS).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:50.747985+00:00"}
{"study_id": 75832, "supplement_id": 1364, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and tolerability of calmangafodipir co-treatment with N-Acetylcysteine (NAC) for paracetamol overdose and assess its potential to reduce biomarkers of toxicity.", "results_summary": "The study found that calmangafodipir was well-tolerated when combined with NAC and may reduce biomarkers of paracetamol toxicity, such as keratin-18 and ccK18, compared to NAC alone. No adverse events were definitively linked to calmangafodipir, and secondary safety outcomes showed no significant differences between groups.", "population_specificity": "Adults within 24 hours of a paracetamol overdose requiring NAC treatment.", "effective_dosage": "NAC was administered alongside calmangafodipir at doses of 2, 5, or 10 \u03bcmol/kg (single intravenous dose).", "study_duration": "Single-dose intervention with follow-up monitoring.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:52.697457+00:00"}
{"study_id": 75836, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the potential of N-Acetylcysteine as a pharmaceutical antioxidant for targeting oxidative stress toxicity in various pathological conditions.", "results_summary": "The study highlights N-Acetylcysteine as a promising antioxidant drug capable of targeting oxidative stress pathways, with potential for clinical use in combination therapies like with Deferiprone. It suggests that effective protocols could enhance therapeutic outcomes.", "population_specificity": "Not specified (general discussion on oxidative stress-related pathologies).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:53.796404+00:00"}
{"study_id": 75834, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to examine the effect of N-acetylcysteine on liver and kidney function tests after surgical bypass in patients with obstructive jaundice.", "results_summary": "N-acetylcysteine significantly improved liver function markers (AST, ALT, ALP, GGT, bilirubin) postoperatively but did not significantly affect serum creatinine levels or reduce hospital/ICU stays.", "population_specificity": "30 patients with obstructive jaundice undergoing bypass surgery.", "effective_dosage": "200 mg/kg per hour for the first 8 hours, followed by 100 mg/kg per hour for another 16 hours, then the same dose for another 24 hours.", "study_duration": "48 hours total.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:54.068633+00:00"}
{"study_id": 75833, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 90, "quality_score": 70, "study_goal": "The researchers aimed to review the clinical course, diagnosis, and treatment of acetaminophen toxicity, focusing on the role of N-Acetylcysteine (NAC) in preventing hepatotoxicity and improving outcomes in acute liver failure.", "results_summary": "NAC effectively prevents hepatotoxicity when administered early after acetaminophen ingestion by maintaining intracellular glutathione stores to detoxify NAPQI. It is generally well-tolerated, though anaphylactoid reactions can occur during loading doses but are easily managed. There is concern that current NAC dosing may be insufficient for large acetaminophen ingestions.", "population_specificity": "Adults with acute or chronic acetaminophen toxicity, including those presenting with liver failure.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:54.464515+00:00"}
{"study_id": 75835, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to synthesize existing studies on the therapeutic effects of N-Acetylcysteine (NAC) against obesity-associated complications, focusing on inflammation, oxidative stress, and metabolic dysregulation.", "results_summary": "The review found strong evidence supporting NAC's ability to reduce inflammation, oxidative stress, and lipid accumulation while improving insulin sensitivity in both in vitro and in vivo obesity models. However, optimal dosage and comparative efficacy with other treatments remain understudied.", "population_specificity": "In vitro and in vivo models of obesity (not human subjects).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:54.943813+00:00"}
{"study_id": 75837, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate N-Acetylcysteine as a potential cardioprotective therapy to reduce infarct size in reperfused STEMI patients.", "results_summary": "The abstract mentions N-Acetylcysteine as a promising pharmacological therapy for reducing infarct size in STEMI, but it does not provide specific efficacy data or outcomes from clinical trials.", "population_specificity": "Patients with reperfused ST-segment elevation myocardial infarction (STEMI).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:58.103071+00:00"}
{"study_id": 75839, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy and safety of N-Acetylcysteine (NAC) with other mucolytic/antioxidant agents (erdosteine and carbocysteine) in reducing acute exacerbations and hospitalizations in COPD patients.", "results_summary": "NAC reduced the duration of acute exacerbations in COPD patients but was less effective than erdosteine and carbocysteine in reducing the risk of exacerbations and hospitalizations. Adverse events were mild and well-tolerated.", "population_specificity": "Chronic obstructive pulmonary disease (COPD) patients (n=2753 across 7 RCTs).", "effective_dosage": "1200 mg/day", "study_duration": "Not specified in the abstract", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:59.784331+00:00"}
{"study_id": 75838, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of N-Acetylcysteine (NAC) as a take-home pharmacotherapy for reducing methamphetamine use and related clinical outcomes in dependent individuals.", "results_summary": "The study is ongoing (N-ICE trial), so no results on NAC's effects on methamphetamine use or related outcomes are reported yet. The abstract outlines the methodology and planned assessments but does not provide findings.", "population_specificity": "Adults dependent on methamphetamine, interested in reducing use, and not currently receiving treatment for substance use disorders (N=180 across three Australian sites).", "effective_dosage": "2400 mg oral NAC daily (two 600 mg capsules in the morning and two in the evening).", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:00.760643+00:00"}
{"study_id": 75842, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to review recent human studies evaluating N-Acetylcysteine's effects on alcohol-related outcomes as part of medication development for alcohol use disorder (AUD).", "results_summary": "The abstract mentions N-Acetylcysteine as one of the compounds tested for AUD, but no specific findings or limitations regarding its effects are detailed.", "population_specificity": "Individuals with alcohol use disorder (AUD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:01.834499+00:00"}
{"study_id": 75840, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 50, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine, in combination with other treatments, could help achieve remission in a Jehovah's Witness patient with acquired thrombotic thrombocytopenic purpura (aTTP) without using plasma or plasma exchange.", "results_summary": "The patient improved clinically and achieved remission lasting over 7 months after receiving N-Acetylcysteine alongside other treatments, suggesting it may contribute to positive outcomes in aTTP management. However, the abstract does not isolate N-Acetylcysteine's specific effects.", "population_specificity": "A Jehovah's Witness patient with acquired thrombotic thrombocytopenic purpura (aTTP) who declined blood products.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:02.518458+00:00"}
{"study_id": 75843, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to validate biomarkers for monitoring the biological effects of a high-dose antioxidant combination (including N-Acetylcysteine) and assess its impact on clinical outcomes in AMN patients.", "results_summary": "The study found that the antioxidant combination normalized most oxidative damage and inflammation biomarkers, improved or stabilized the 6-minute walk test in 8/10 subjects, and reduced central motor conduction time.", "population_specificity": "13 subjects with adrenomyeloneuropathy (AMN), the adult-onset variant of X-linked adrenoleukodystrophy.", "effective_dosage": "High dose (specific amount not detailed in abstract), combined with \u03b1-tocopherol and \u03b1-lipoic acid.", "study_duration": "Not specified in abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:03.903330+00:00"}
{"study_id": 75841, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine whether mucolytics, including N-Acetylcysteine, reduce exacerbations and days of disability in patients with chronic bronchitis or COPD, while also assessing effects on lung function, quality of life, and adverse events.", "results_summary": "The study found that mucolytics, including N-Acetylcysteine, may reduce exacerbations and days of disability, with a modest improvement in quality of life and possible reduction in hospitalizations, though effects were smaller in more recent studies and heterogeneity was high.", "population_specificity": "Adults with chronic bronchitis or COPD (excluding asthma and cystic fibrosis).", "effective_dosage": "At least once daily (specific dosage not detailed in the abstract).", "study_duration": "Between two months and three years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:03.904731+00:00"}
{"study_id": 75844, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 85, "quality_score": 90, "study_goal": "To determine if intravenous N-Acetylcysteine (NAC) reduces the incidence of post-embolization syndrome in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE).", "results_summary": "Intravenous NAC significantly reduced the incidence of post-embolization syndrome (24.6% vs. 48.2% in placebo) but did not prevent post-TACE liver decompensation. Multivariate analysis confirmed NAC's association with reduced syndrome occurrence.", "population_specificity": "HCC patients admitted for TACE, stratified by Child A or B liver function.", "effective_dosage": "150 mg/kg/h for 1 h, then 12.5 mg/kg/h for 4 h, followed by continuous infusion of 6.25 mg/h for 48 h post-procedure.", "study_duration": "48 hours post-TACE.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:05.437812+00:00"}
{"study_id": 75845, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 40, "quality_score": 80, "study_goal": "The researchers aimed to determine whether adding N-Acetylcysteine (NAC) to standard care improves perioperative outcomes in adult patients undergoing cardiac surgery.", "results_summary": "The study found that NAC did not result in statistically significant reductions in mortality, acute renal insufficiency, acute cardiac insufficiency, hospital or ICU length of stay, arrhythmia, or acute myocardial infarction. The evidence was of low to moderate certainty, with no clear clinical benefit observed.", "population_specificity": "Adult patients undergoing cardiac surgery, including those with and without kidney dysfunction.", "effective_dosage": "Not specified (heterogeneity in dosage, route, and duration across studies).", "study_duration": "Not specified (varied across studies).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:07.374575+00:00"}
{"study_id": 75849, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were examining the potential of pharmacotherapy, including N-Acetylcysteine, for treating substance use disorders in adolescents and young adults.", "results_summary": "The abstract does not provide specific findings about N-Acetylcysteine's effects, only noting the limited literature on pharmacotherapy for adolescent SUD.", "population_specificity": "Adolescents and young adults with substance use disorders.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:09.422642+00:00"}
{"study_id": 75847, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "To assess the efficacy and safety of simethicone with or without N-acetylcysteine (NAC) as premedications before gastroscopy.", "results_summary": "Simethicone plus NAC showed higher rates of positive findings and better mucosal visibility compared to water, but no significant difference compared to simethicone alone. The combination also reduced procedure time without significant adverse events.", "population_specificity": "5,750 patients undergoing gastroscopy.", "effective_dosage": "Not specified", "study_duration": "Single administration before gastroscopy", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:09.800795+00:00"}
{"study_id": 75848, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the long-term effects of a treatment algorithm including N-Acetylcysteine on lung function, antibiotic use, and exacerbation rates in Bronchiectasis patients.", "results_summary": "The study found that the treatment algorithm, which included N-Acetylcysteine, helped reduce lung function decline, antibiotic use, and hospitalization rates over a 12-month period.", "population_specificity": "Patients with Bronchiectasis and >2 exacerbations with significant symptom burden.", "effective_dosage": "Inhaled daily or twice daily (specific dosage not specified).", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:11.137006+00:00"}
{"study_id": 75850, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine combined with working memory training could improve neural mechanisms of cue reactivity and working memory in cocaine users.", "results_summary": "The study found no confirmation of the hypotheses, possibly due to small sample size, low adherence to working memory training, or ongoing substance use. Exploratory whole brain analyses were performed, but no significant effects were reported.", "population_specificity": "Cocaine-using men (24 out of 38 completed the study).", "effective_dosage": "2400 mg/day NAC", "study_duration": "25 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:12.166538+00:00"}
{"study_id": 75851, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of N-Acetylcysteine (NAC) in modulating inflammatory responses, particularly HMGB1 connectivity, in pediatric acute liver failure (PALF) survivors and non-survivors with acetaminophen overdose (APAPo).", "results_summary": "NAC was associated with reduced HMGB1 network connectivity in APAPo survivors, suggesting an anti-inflammatory effect. In vitro studies recapitulated these findings, showing altered inflammatory responses in HMGB1-null hepatocytes treated with APAP + NAC.", "population_specificity": "Pediatric patients with acute liver failure (APAPo and non-APAPo) and mouse hepatocytes.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:13.264338+00:00"}
{"study_id": 75852, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether long-term use of N-acetylcysteine reduces the risk of exacerbations in bronchiectasis patients.", "results_summary": "The study found that N-acetylcysteine significantly reduced the incidence of exacerbations compared to on-demand treatment, with fewer exacerbations per patient-year and a higher percentage of patients remaining exacerbation-free.", "population_specificity": "Adult bronchiectasis patients in Shandong Province, China, with at least two exacerbations in the past year.", "effective_dosage": "600 mg, twice daily", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:13.775500+00:00"}
{"study_id": 75853, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the potential therapeutic role of N-Acetylcysteine in systemic lupus erythematosus (SLE), focusing on its mechanisms of action and efficacy independent of immunosuppressive effects.", "results_summary": "The abstract suggests N-Acetylcysteine is among non-immunosuppressive agents with potential benefits for SLE management, but specific efficacy results are not detailed. The review critically discusses its mechanisms and therapeutic potential.", "population_specificity": "Patients with systemic lupus erythematosus (SLE).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:15.799167+00:00"}
{"study_id": 75854, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the association between blunt and joint use frequency and cannabis use characteristics and consequences among past-month cannabis users in the context of N-Acetylcysteine treatment for cannabis cessation.", "results_summary": "The study found that blunt use frequency predicted higher cannabis consumption, cost, and withdrawal symptoms, while joint use did not. N-Acetylcysteine's specific effects were not detailed in the abstract.", "population_specificity": "Past-month cannabis users (N=377) screened for participation in a cannabis cessation study.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:17.868514+00:00"}
{"study_id": 75856, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) could increase decay-accelerating factor (DAF) levels and inhibit complement activation in patients with transplant-associated thrombotic microangiopathy (TA-TMA).", "results_summary": "NAC increased DAF levels and inhibited complement activation in human umbilical vein endothelial cells (HUVECs) incubated with TA-TMA plasma, suggesting its potential as a therapy for TA-TMA.", "population_specificity": "Patients with transplant-associated thrombotic microangiopathy (TA-TMA) and human umbilical vein endothelial cells (HUVECs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:18.844551+00:00"}
{"study_id": 75858, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether N-acetylcysteine could prevent the formation of persister cells in Mycobacterium tuberculosis cultures by enhancing bacterial respiration.", "results_summary": "N-acetylcysteine, along with vitamin C, was found to prevent the formation of persister cells in M. tuberculosis cultures by enhancing respiration, thereby improving the effectiveness of isoniazid treatment.", "population_specificity": "Mycobacterium tuberculosis bacterial cultures", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:20.608253+00:00"}
{"study_id": 75857, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to comprehensively explore the effects of anti-inflammatory agents, including N-Acetylcysteine, on symptoms, cognitive function, general functioning, and side effects in patients with schizophrenia.", "results_summary": "The study did not specifically report findings for N-Acetylcysteine, focusing instead on overall anti-inflammatory agents, which showed significant symptom reduction and cognitive improvements without increased side effects.", "population_specificity": "Patients with schizophrenia (2,914 participants across 62 studies).", "effective_dosage": "Not specified for N-Acetylcysteine.", "study_duration": "Not specified for N-Acetylcysteine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:20.820744+00:00"}
{"study_id": 75859, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to review the limited available evidence on the use of N-Acetylcysteine and other pharmacologic agents for managing self-injurious behaviors in children with neurodevelopmental disorders.", "results_summary": "The abstract mentions N-Acetylcysteine as one of the less common agents reviewed, but it does not provide specific findings on its efficacy or safety, indicating a need for additional well-designed studies.", "population_specificity": "Children with neurodevelopmental disorders exhibiting self-injurious behaviors.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:21.162754+00:00"}
{"study_id": 75861, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 85, "study_goal": "The researchers aimed to compare the effectiveness of N-Acetylcysteine (NAC) with other preventive strategies, including statins and saline, in reducing the risk of contrast-induced acute kidney injury (CIAKI) in patients undergoing cardiac catheterization.", "results_summary": "The study found that statins were superior to NAC in reducing the risk of CIAKI, with no significant differences observed between NAC and other treatments in terms of hemodialysis risk or all-cause mortality. NAC alone or in combination with sodium bicarbonate or saline did not show statistically significant advantages over placebo or normal saline.", "population_specificity": "Patients undergoing cardiac catheterization (28,063 total participants, with 3,006 receiving NAC).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:23.464639+00:00"}
{"study_id": 75862, "supplement_id": 1364, "safety_score": "70", "efficacy_score": 45, "quality_score": 60, "study_goal": "The researchers aimed to assess the efficacy and safety of N-acetylcysteine (NAC) as an adjuvant therapy to antibiotics for Helicobacter pylori eradication.", "results_summary": "The study found uncertain evidence regarding whether NAC improves H. pylori eradication rates compared to placebo or no NAC, with mixed results in subgroup analyses. There was also uncertainty about NAC's association with gastrointestinal or allergic adverse events, though no toxic adverse events were reported.", "population_specificity": "Adults aged 17-76 years with H. pylori infection, recruited from endoscopy centers in various countries.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:24.635519+00:00"}
{"study_id": 75865, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine if adjunctive N-acetylcysteine (NAC) is effective for treating acute bipolar depression.", "results_summary": "The study found no statistically or clinically significant difference in depressive symptoms between NAC and placebo groups. All secondary outcomes were also insignificant, suggesting NAC did not improve acute bipolar depression in this trial.", "population_specificity": "Adults diagnosed with bipolar disorder experiencing a depressive episode.", "effective_dosage": "3 g/day", "study_duration": "20 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:28.179938+00:00"}
{"study_id": 75863, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether smoking status or concomitant medication use influenced the efficacy of N-Acetylcysteine (NAC) in reducing COPD exacerbations, particularly using healthcare resource utilization (HCU) criteria.", "results_summary": "NAC reduced the rate of HCU-defined exacerbations by 20%, with a stronger effect (23%) in current/ex-smokers. A 60% reduction in exacerbations was observed in patients receiving NAC and long-acting bronchodilators without inhaled corticosteroids (ICS) compared to those on placebo, bronchodilators, and ICS.", "population_specificity": "Current, ex-, and never-smokers with COPD, including those on concomitant medications.", "effective_dosage": "600 mg twice daily", "study_duration": "Not specified", "interactions": "Reduced efficacy when combined with ICS; enhanced efficacy with long-acting bronchodilators.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:28.307211+00:00"}
{"study_id": 75864, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to review the immunomodulating and therapeutic effects of N-Acetylcysteine (NAC) on respiratory tract mucosal immunity and its role in managing mucostasis-related diseases.", "results_summary": "NAC demonstrated pleiotropic immunomodulating properties, improving mucus rheology, reducing mucin production, restoring mucociliary clearance, enhancing sIgA production, suppressing excessive IgE and IgG4, disrupting biofilms, inhibiting bacterial adhesion, and regulating cytokines. No evidence suggested NAC suppresses mucosal immunity, though further research is needed for definitive conclusions.", "population_specificity": "Not specified (literature review, likely encompassing various respiratory disease populations).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:28.746414+00:00"}
{"study_id": 75846, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to evaluate N-acetylcysteine as a promising new therapy for alcoholic hepatitis (AH) and its potential role in treating alcohol-related liver disease (ALD).", "results_summary": "The abstract mentions N-acetylcysteine as a promising new therapy for AH, but specific efficacy results or outcomes are not detailed. It highlights the need for novel therapeutic targets in ALD.", "population_specificity": "Patients with alcohol-related liver disease, particularly those with alcoholic hepatitis (AH).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:29.136380+00:00"}
{"study_id": 75866, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate N-Acetylcysteine's potential as a neuroprotective agent in neuropsychiatric disorders by examining its mechanisms and clinical efficacy.", "results_summary": "N-Acetylcysteine was found to inhibit pathways of neuroprogression, such as oxidative stress and inflammatory gene expression, and showed potential in preventing neural damage or cognitive decline. However, definitive clinical efficacy remains to be confirmed.", "population_specificity": "Patients with neuropsychiatric disorders (e.g., depression, bipolar disorder, schizophrenia).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:29.472249+00:00"}
{"study_id": 75867, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to assess the effectiveness and safety of pharmacotherapies, including N-Acetylcysteine, for reducing cannabis withdrawal symptoms and promoting cessation or reduction of cannabis use.", "results_summary": "The evidence base for N-Acetylcysteine is weak, but it is considered worth further investigation. The study found no strong evidence of efficacy for N-Acetylcysteine in treating cannabis dependence, though it may have some potential.", "population_specificity": "Adults and young people (mean age 20 to 41 years) diagnosed as cannabis dependent or likely to be dependent, with 75% male participants.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:31.026864+00:00"}
{"study_id": 75869, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to review the safety and efficacy of N-Acetylcysteine (NAC) in treating pathologic grooming disorders, including trichotillomania, onychophagia, and pathological skin picking.", "results_summary": "The review found that NAC was generally safe with mild side effects, mostly gastrointestinal, and showed mostly positive results in treating grooming disorders, though evidence was limited by few randomized controlled trials.", "population_specificity": "Patients with pathologic grooming disorders (trichotillomania, onychophagia, pathological skin picking).", "effective_dosage": "450 to 2,400 mg per day (oral).", "study_duration": "1 to 8 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:33.251182+00:00"}
{"study_id": 75868, "supplement_id": 1364, "safety_score": "70", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to examine the efficacy of N-acetylcysteine (NAC) alone and in combination with nutraceutical agents for treating bipolar depression, focusing on mitochondrial bioenergetics.", "results_summary": "The study found no significant differences between NAC, NAC with combination treatment, and placebo at the primary endpoint (16 weeks). However, some secondary outcomes showed improvement in the combination group at week 20, suggesting delayed or withdrawal-related effects. Gastrointestinal symptoms were more frequent with NAC than placebo.", "population_specificity": "Adults with bipolar disorder and current depressive symptoms (n=181, analyzed n=148).", "effective_dosage": "2000 mg/day NAC.", "study_duration": "16 weeks (with follow-up to week 20).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:33.459003+00:00"}
{"study_id": 75870, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to identify plasma proteins differentially expressed in response to antioxidant cocktails, including N-Acetylcysteine, in thalassemic patients to understand their therapeutic mechanisms.", "results_summary": "The study identified altered expression levels of specific plasma proteins in response to antioxidant cocktails, including associations between VTN and bilirubin levels and PON1 and oxidative stress markers, consistent with proteomic findings.", "population_specificity": "\u03b2-thalassemia/Hb E patients", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:35.901718+00:00"}
{"study_id": 75873, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to identify whether N-Acetylcysteine is effective and safe as an adjunct therapy to conventional antidepressants for major depressive disorder.", "results_summary": "The study identified N-Acetylcysteine as one of several agents potentially effective in augmenting standard antidepressant treatment, with preclinical and clinical evidence supporting its efficacy. However, specific efficacy data for N-Acetylcysteine alone were not detailed in the abstract.", "population_specificity": "Patients with major depressive disorder (MDD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:37.430867+00:00"}
{"study_id": 75874, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to explore the potential role of N-Acetylcysteine as a dietary intervention in the treatment of bipolar disorder.", "results_summary": "The abstract suggests that N-Acetylcysteine, along with other nutrients, may enhance treatment outcomes for bipolar disorder by indirectly and directly affecting brain function and improving patient engagement in treatment. However, specific efficacy data for N-Acetylcysteine alone are not detailed.", "population_specificity": "Patients with bipolar disorder.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:37.857315+00:00"}
{"study_id": 75871, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to assess the antioxidative effect of N-Acetylcysteine (NAC) in sepsis patients and compare the efficacy of intermittent versus continuous infusion regimens.", "results_summary": "NAC significantly increased total antioxidant capacity (TAC) in both intermittent and continuous infusion groups, with no significant difference between the two methods. The study confirmed NAC's antioxidative effect in sepsis patients.", "population_specificity": "60 critically ill patients with sepsis (20 in intermittent infusion group, 20 in continuous infusion group, and 20 controls).", "effective_dosage": "Intermittent: 25 mg/kg bolus followed by 25 mg/kg every 8 hours (3 times); Continuous: 25 mg/kg bolus followed by 75 mg/kg over 24 hours.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:38.385285+00:00"}
{"study_id": 75872, "supplement_id": 1364, "safety_score": "70", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to investigate the safety and tolerability of N-Acetylcysteine (NAC) in combination with a superoxide dismutase mimetic (PP100-01) for treating paracetamol overdose, compared to NAC alone.", "results_summary": "The study found that NAC, while effective, is associated with adverse reactions like nausea, vomiting, and anaphylactoid reactions. The combination with PP100-01 is being explored to potentially improve efficacy, especially in late-presenting patients.", "population_specificity": "Patients treated for paracetamol overdose within 24 hours of ingestion.", "effective_dosage": "NAC regimen over 12 hours (specific dosage not detailed in abstract); PP100-01 tested at 2, 5, and 10 \u03bcmol/kg.", "study_duration": "12-hour NAC regimen.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:39.120294+00:00"}
{"study_id": 75876, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to determine whether combining N-Acetylcysteine (NAC) with aspirin could enhance treatment response for depressive symptoms in bipolar disorder.", "results_summary": "After 16 weeks, NAC + aspirin showed a higher probability of treatment response (67%) compared to placebo (55%), NAC alone (57%), and aspirin alone (33%). No significant effects were observed on inflammatory markers (interleukin-6 and C-reactive protein).", "population_specificity": "Medicated patients aged 18-65 with DSM-IV-TR bipolar disorder and a MADRS score \u2265 20.", "effective_dosage": "1,000 mg NAC daily.", "study_duration": "16 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:39.882599+00:00"}
{"study_id": 75877, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to summarize findings related to ischemia-reperfusion injury following total knee arthroplasty, including potential protective interventions like N-Acetylcysteine.", "results_summary": "The abstract does not specifically mention N-Acetylcysteine's effects, focusing instead on other interventions like propofol, ischemic preconditioning, and vitamin C.", "population_specificity": "Patients undergoing total knee arthroplasty with tourniquet-induced ischemia-reperfusion injury.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:41.298367+00:00"}
{"study_id": 75878, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 70, "study_goal": "The researchers aimed to investigate the association between prior exposure to N-acetylcysteine and the risk of noncatheter-related Candida bloodstream infections (CBSI) in adult ICU patients.", "results_summary": "The study found that prior exposure to N-acetylcysteine was associated with a significantly reduced risk of CBSI (subdistribution hazard ratio: 0.11, 95% CI: 0.03-0.34). However, due to the limited number of subjects exposed to N-acetylcysteine, the results were interpreted with caution.", "population_specificity": "Nonneutropenic adult patients admitted to intensive care units (ICUs).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:43.215630+00:00"}
{"study_id": 75880, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not mention N-Acetylcysteine or its study.", "results_summary": "The abstract does not discuss N-Acetylcysteine or its effects.", "population_specificity": "Patients with alcoholic hepatitis.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:43.382251+00:00"}
{"study_id": 75879, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) modifies the pain efficacy of paracetamol (APAP) and prevents glutathione depletion when co-administered with APAP at therapeutic doses.", "results_summary": "The study evaluated NAC's effects on APAP pain efficacy and glutathione levels in healthy volunteers, but the abstract does not specify the outcomes regarding NAC's impact on pain or glutathione depletion.", "population_specificity": "24 healthy volunteers", "effective_dosage": "APAP (1 g \u00d74 daily) with NAC or placebo", "study_duration": "4 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:43.839244+00:00"}
{"study_id": 75881, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to synthesize current evidence on N-Acetylcysteine's effectiveness as an adjunctive therapy for psychiatric conditions, including addiction, schizophrenia, obsessive-compulsive disorders, and mood disorders.", "results_summary": "N-Acetylcysteine showed good efficacy in reducing schizophrenia symptoms and substance use cravings, particularly for cocaine and cannabis in young people. Effects on obsessive-compulsive and mood disorders were mixed, requiring further study.", "population_specificity": "Individuals with psychiatric conditions (schizophrenia, addiction, obsessive-compulsive disorders, mood disorders).", "effective_dosage": "2000-2400 mg/day.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:46.293986+00:00"}
{"study_id": 75882, "supplement_id": 1364, "safety_score": "100", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of inhaled N-Acetylcysteine (NAC) in enhancing airway clearance and improving respiratory outcomes in adults with acute respiratory conditions.", "results_summary": "The study found no adverse events associated with NAC (n=50). NAC showed no effect on mucus during invasive ventilation but improved mucus characteristics postoperatively (n=10). Overall, NAC was deemed ineffective for atelectasis/mucus plugging while intubated.", "population_specificity": "Adults with acute respiratory conditions, including those undergoing invasive ventilation and postoperative care.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:46.984168+00:00"}
{"study_id": 75883, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of adding N-acetylcysteine (NAC) to conventional treatment versus conventional treatment alone on oxidative stress, inflammatory factors, and radiological changes in community-acquired pneumonia (CAP) patients.", "results_summary": "The study found that NAC reduced malondialdehyde (MDA) and tumor necrosis factor-\u03b1 (TNF-\u03b1) levels while increasing total antioxidant capacity (TAOC), but did not significantly affect superoxide dismutase (SOD) activity or CT scores compared to conventional treatment alone. No NAC-related adverse effects were observed.", "population_specificity": "CAP patients at Weihai Municipal Hospital.", "effective_dosage": "1200 mg/d", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:48.175193+00:00"}
{"study_id": 75884, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to review diagnostic features and discuss therapeutic strategies, including nongenetic approaches, for RYR1-related myopathies.", "results_summary": "The abstract does not provide specific findings on N-Acetylcysteine's effects, focusing instead on diagnostic methods and potential therapeutic strategies for RYR1-RM.", "population_specificity": "Patients with RYR1-related myopathies (RYR1-RM).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:48.912529+00:00"}
{"study_id": 75885, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of Chinese herbal medicines (CHMs) with N-acetylcysteine (NAC) in treating idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study evaluated CHMs versus NAC in IPF treatment, assessing outcomes like acute exacerbation, mortality, lung function, and quality of life, but did not provide specific comparative results for NAC alone.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (IPF).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:48.969420+00:00"}
{"study_id": 75886, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the anxiolytic effects of N-Acetylcysteine (NAC) by reviewing data from animal studies and clinical trials, focusing on its multitarget mechanisms involving oxidative stress, neuroinflammation, and glutamatergic dysfunction.", "results_summary": "NAC showed consistent anxiolytic effects in various animal models and preliminary clinical trials, with good safety profiles and tolerance to adverse effects, suggesting potential as an innovative and better-tolerated anxiolytic.", "population_specificity": "Patients with anxiety and/or anxiety-related disorders.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:51.220718+00:00"}
{"study_id": 75888, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) as an add-on therapy could improve neurocognition and reduce symptoms in early psychosis patients, particularly those with high peripheral oxidative status.", "results_summary": "NAC significantly improved processing speed (neurocognition) and reduced positive symptoms in patients with high oxidative stress, while also increasing glutathione levels in the medial prefrontal cortex by 23%.", "population_specificity": "Early psychosis patients.", "effective_dosage": "2700 mg/day.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:51.749238+00:00"}
{"study_id": 75887, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine in preventing contrast-induced acute kidney injury (CI-AKI) in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI).", "results_summary": "The abstract suggests that N-Acetylcysteine's role in CI-AKI prevention has been challenged, indicating mixed or inconclusive efficacy compared to other strategies like guided hydration or high-dose statins. Recent studies have not strongly supported its use, though it remains part of the discussion for PCI complications.", "population_specificity": "Patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:52.400366+00:00"}
{"study_id": 75890, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine whether oral N-acetylcysteine is as effective as intravenous N-acetylcysteine in managing paracetamol overdose.", "results_summary": "The study found that oral N-acetylcysteine is a safe alternative to intravenous administration when the latter is not an option, based on seven relevant studies. The clinical bottom line supports its use in such cases.", "population_specificity": "Patients with paracetamol overdose.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:54.045959+00:00"}
{"study_id": 75889, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of oral N-Acetylcysteine (NAC) on inflammatory cytokines and oxidative stress in patients with Rheumatoid Arthritis (RA).", "results_summary": "NAC significantly reduced oxidative stress markers (MDA, NO) and inflammatory cytokines (IL-6, TNF-\u03b1, CRP, ESR) while increasing antioxidant parameters (TAC, TTG). However, only NO, MDA, and TTG showed significant differences compared to placebo.", "population_specificity": "Patients with Rheumatoid Arthritis (23 in NAC group, 19 in placebo group).", "effective_dosage": "600 mg twice daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:55.127477+00:00"}
{"study_id": 75892, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore N-Acetylcysteine as a potential therapeutic intervention for neurological and neuropsychiatric disorders by addressing blood-brain barrier dysfunction linked to inflammatory and oxidative stress.", "results_summary": "The study suggests N-Acetylcysteine, alongside other interventions, may help mitigate blood-brain barrier dysfunction caused by chronic inflammatory and oxidative stress, potentially benefiting neurological and neuropsychiatric conditions.", "population_specificity": "Not specified (general focus on neurological and neuropsychiatric disorders)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:56.883206+00:00"}
{"study_id": 75893, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine how N-Acetylcysteine affects tobacco use in cannabis-dependent individuals and whether nicotine dependence influences cannabis cessation.", "results_summary": "N-Acetylcysteine reduced cigarette smoking in those with lower baseline nicotine dependence but slightly increased smoking in those with moderate/high dependence. Nicotine dependence did not affect cannabis abstinence.", "population_specificity": "Treatment-seeking adults (ages 18-50) with cannabis dependence, including cigarette smokers (n=117).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:56.934507+00:00"}
{"study_id": 75896, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine, as a methylglyoxal scavenger, could prevent cardiovascular and renal complications in diabetes.", "results_summary": "The study suggests that N-Acetylcysteine may help mitigate methylglyoxal-induced damage, potentially reducing diabetic complications, but clinical evidence supporting its efficacy is limited and requires further investigation.", "population_specificity": "Patients with diabetes mellitus at risk of cardiovascular and renal complications.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:59.371453+00:00"}
{"study_id": 75895, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate whether adding N-Acetylcysteine and other antioxidants to standard H. pylori eradication therapy improves efficacy and safety.", "results_summary": "The study found that N-Acetylcysteine, when combined with amoxicillin-clarithromycin-based therapy, improved H. pylori eradication rates, but overall, antioxidants did not significantly enhance eradication or reduce side effects compared to standard therapy alone.", "population_specificity": "1260 participants across 9 studies, focusing on H. pylori-infected individuals.", "effective_dosage": "Not specified for N-Acetylcysteine (only vitamin dosage mentioned: 1400 mg/day).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:59.843027+00:00"}
{"study_id": 75898, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to examine the evidence for redox-mediating drugs, particularly N-acetylcysteine, as a potential treatment for cocaine addiction.", "results_summary": "The abstract suggests that N-acetylcysteine may influence the response to drugs of abuse through redox-sensitive signaling, particularly S-glutathionylation, but does not provide specific efficacy results. The review calls for further research to advance the field.", "population_specificity": "Focused on individuals with substance use disorder (SUD), specifically cocaine addiction.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:02.244441+00:00"}
{"study_id": 75897, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the efficacy of N-acetylcysteine (NAC) as an add-on therapy for treatment-resistant depression (TRD) in patients with increased inflammatory activity and explore its potential roles in inflammation and oxidative stress.", "results_summary": "The study found that NAC supplementation as an add-on to standard antidepressant therapy may improve treatment outcomes in TRD patients with elevated inflammatory markers, though specific efficacy results were not detailed in the abstract. Secondary outcomes included changes in pathophysiological mechanisms, brain activity, and white matter integrity.", "population_specificity": "Patients with treatment-resistant depression (TRD) and increased inflammatory activity (CRP levels between 0.85 and 10 mg/L).", "effective_dosage": "Not specified in the abstract.", "study_duration": "12-week treatment with an 8-week follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:02.974919+00:00"}
{"study_id": 75901, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the clinical benefit of N-Acetylcysteine in treating drug-induced liver injury (DILI) alongside other interventions.", "results_summary": "The study suggests that N-Acetylcysteine, when used in selected patients, shows some clinical benefit for DILI, but additional prospective studies are needed to confirm its efficacy.", "population_specificity": "Patients with drug-induced liver injury (DILI).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:04.320563+00:00"}
{"study_id": 75899, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the pharmacokinetics of triptolide, including its biotransformation pathways involving N-Acetylcysteine (NAC) conjugation.", "results_summary": "The study found that triptolide undergoes biotransformation in rats, including conjugation with NAC, but did not specifically evaluate NAC's efficacy or safety. Less than 4% of triptolide was recovered in excreta within 24 hours.", "population_specificity": "Rats (animal study)", "effective_dosage": "Not specified for NAC", "study_duration": "Not specified for NAC", "interactions": "Triptolide interacts with P-glycoprotein (P-gp) and CYP3A4 substrates/inhibitors, but NAC interactions were not specifically mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:04.401445+00:00"}
{"study_id": 75903, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to explore the potential of N-Acetylcysteine as an antioxidant therapy to mitigate sulfur mustard-induced oxidative stress damages.", "results_summary": "The study suggests that N-Acetylcysteine may help counteract oxidative stress caused by sulfur mustard by restoring glutathione levels and reducing reactive oxygen species, though clinical efficacy is not quantified.", "population_specificity": "Not specified (theoretical application to sulfur mustard exposure).", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:07.533233+00:00"}
{"study_id": 75902, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to compare the otoprotective effects of transtympanic injections of N-acetylcysteine and dexamethasone in preventing cisplatin-induced ototoxicity.", "results_summary": "N-acetylcysteine showed no significant changes in auditory thresholds, indicating effective otoprotection, while dexamethasone resulted in significant hearing threshold decreases at 8000 Hz. The study concluded that N-acetylcysteine is a safe and effective strategy for preventing cisplatin-induced ototoxicity.", "population_specificity": "60 cisplatin-treated patients at Shahid Sadoughi Hospital (2016-2017).", "effective_dosage": "10% N-acetylcysteine transtympanic injection.", "study_duration": "Six months (follow-up after each cisplatin cycle).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:08.431318+00:00"}
{"study_id": 75904, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine supplementation could enhance performance and reduce soreness in semi-elite rugby players during high-intensity, repeated-sprint exercise.", "results_summary": "The abstract does not provide specific results, but the study investigated potential benefits of NAC for performance and soreness reduction in athletes.", "population_specificity": "17 semi-elite male rugby union players", "effective_dosage": "1 g oral NAC", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:09.811991+00:00"}
{"study_id": 75905, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the bioequivalence of a new N-acetylcysteine 2% oral solution compared to an approved reference formulation in healthy subjects.", "results_summary": "The new N-acetylcysteine 2% oral solution demonstrated bioequivalence to the reference formulation, with pharmacokinetic parameters falling within the predefined range (80\u2013125%). Most adverse events were mild or moderate and not attributed to the study drug.", "population_specificity": "Healthy subjects", "effective_dosage": "N-acetylcysteine 2% oral solution (specific dosage frequency not detailed in abstract)", "study_duration": "Not specified in abstract", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:12.780127+00:00"}
{"study_id": 75900, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine if AST/ALT, CK/AST, and CK/ALT ratios could differentiate rhabdomyolysis from acetaminophen toxicity, potentially reducing unnecessary N-acetylcysteine treatment.", "results_summary": "The study found that AST/ALT, CK/AST, and CK/ALT ratios were significantly higher in rhabdomyolysis compared to acetaminophen toxicity, suggesting these ratios could help avoid misdiagnosis and unnecessary N-acetylcysteine use.", "population_specificity": "Patients with a discharge diagnosis of acetaminophen toxicity or rhabdomyolysis from four hospitals (2006-2011).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:17.742310+00:00"}
{"study_id": 75891, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) could reduce post-operative acute kidney injury (AKI) or the need for renal replacement therapy (RRT) following cardiopulmonary bypass (CPB) in cardiac surgery.", "results_summary": "The study found that NAC had no statistically significant benefit in reducing AKI-CPB or the need for RRT following CPB. The results suggest no meaningful clinical impact of NAC in this context.", "population_specificity": "Patients who underwent cardiac surgery via cardiopulmonary bypass.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:20.641374+00:00"}
{"study_id": 27173, "supplement_id": 1396, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the effects of Omega-3 Fatty Acids (O3FAs) as a complementary treatment for inflammation, nutrition levels, post-operative infectious complications, and recovery enhancement in colorectal cancer (CRC) patients.", "results_summary": "O3FAs significantly reduced IL-6, CRP, and TNF-\u03b1 levels but did not affect IL-1\u03b2. They slightly increased serum albumin levels, reduced post-operative infectious complications, and shortened hospital stays.", "population_specificity": "Colorectal cancer (CRC) patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:28.610861+00:00"}
{"study_id": 27170, "supplement_id": 1396, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether Omega-3 Fatty Acids (O3FA) could mitigate BPF-induced hypothyroidism-mediated testicular dysfunction in male Wistar rats.", "results_summary": "O3FA at both low (100mg/kg) and high (300mg/kg) doses improved sperm quality, hormone levels, antioxidant capacity, and reduced inflammatory markers, while preventing BPF-induced cellular dysfunction and protein imbalances.", "population_specificity": "Male Wistar rats", "effective_dosage": "100mg/kg and 300mg/kg of O3FA", "study_duration": "28 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:28.666136+00:00"}
{"study_id": 27175, "supplement_id": 1396, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the pharmacological mechanisms, clinical trial outcomes, and evidence value of Omega-3 fatty acids in preventing and treating atherosclerotic cardiovascular disease (ASCVD).", "results_summary": "The study found that Omega-3 fatty acids have potential benefits in reducing ASCVD risk, but large randomized controlled trials show mixed results, leading to controversy in clinical use. The review highlights the need for further research to clarify their efficacy and application strategies.", "population_specificity": "Individuals at risk of or with atherosclerotic cardiovascular disease (ASCVD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:28.678272+00:00"}
{"study_id": 27177, "supplement_id": 1396, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine Omega-3 fatty acid levels in acne patients and correlate them with dietary preferences and clinical severity.", "results_summary": "The study found that 96% of acne patients had Omega-3 levels below the recommended range (8-11%), with a mean of 5.15%. Higher Omega-3 levels were associated with legume consumption, oral supplementation, and avoiding sunflower oil.", "population_specificity": "100 acne patients in Germany.", "effective_dosage": "Not specified.", "study_duration": "Not specified (cross-sectional study).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:28.852892+00:00"}
